PCT/GB98/02115

REC'D 12 AUG 1998

WIPO PCT

The Patent Office

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

PRIORITY DOCUMENT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 31 July 1998

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
(R...

The Patent Office
16 JUL 1997
LONDON

13JUL97 E289513-1 002923
P01/7700 25.00-9714971.0

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	SMW/BP5620703
2. Patent application number *(The Patent Office will fill in this part)*	9714971.0 16 JUL 1997
3. Full name, address and postcode of the or of each applicant *(underline all surnames)*	CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED CAMBRIDGE HOUSE 6-10 CAMBRIDGE TERRACE REGENT'S PARK NW1 4JL LONDON
Patents ADP number *(if you know it)*	3918150002
If the applicant is a corporate body, give the country/state of its incorporation	UNITED KINGDOM
4. Title of the invention	ASSAYS, THERAPEUTIC METHODS AND MEANS
5. Name of your agent *(if you have one)*	MEWBURN ELLIS
"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*	YORK HOUSE 23 KINGSWAY LONDON WC2B 6HP
Patents ADP number *(if you know it)*	109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month /year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

YES

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	100
Claim(s)	0
Abstract	0
Drawing(s)	9

SJB

10. If you are also filing any of the following, state

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	0
Request for preliminary examination and search *(Patents Form 9/77)*	0
Request for substantive examination *(Patents Form 10/77)*	0
Any other documents *(Please specify)*	0

11. I/We request the grant of a patent on the basis of this application.

Signature [signature] Date 16 July 1997

12. Name and daytime telephone number of person to contact in the United Kingdom: Seán WALTON 0171 240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed it it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

ASSAYS, THERAPEUTIC METHODS AND MEANS

The present invention relates to screening methods, peptides, mimetics, and methods of use based on the surprising discovery and characterisation of an interaction between known proteins, and thus numerous cellular processes of interest in therapeutic contexts. The proteins in question are ATM and p53, and the inventors have found that ATM phosphorylates p53 at a number of specific sites, and likely other proteins at similar sites. Further aspects of the present invention are founded on the discovery that ATM binds DNA and that such binding has an effect on phosphorylation of p53 by ATM.

Ataxia-telangiectasia (A-T) is a human autosomal recessive disorder characterised by a number of debilitating symptoms, including a progressive cerebellar degeneration, occulocutaneous telangiectasia, growth retardation, immune deficiencies and certain characteristics of premature ageing (reviewed in Jackson, 1995; Meyn, 1995; Shiloh, 1995). A-T patients exhibit an approximately 100-fold increased incidence of cancer, with patients being particularly predisposed to malignancies of lymphoid origin. Furthermore, A-T heterozygotes, which comprise ~1% of the population, are reported to exhibit a higher incidence of breast cancer (Easton, 1994; Meyn, 1995), although this remains controversial (Fitzgerald *et al.*, 1997). At the cellular level, A-T is characterised by a high degree of chromosomal

instability, radioresistant DNA synthesis, and hypersensitivity to ionising radiation (IR) and radiomimetic drugs. In addition, A-T cells are defective in the radiation induced G1-S, S, and G2-M cell cycle checkpoints that are thought to arrest the cell cycle in response to DNA damage in order to allow repair of the genome prior to DNA replication or mitosis (Halazonetis *et al.*, 1993; Beamish *et al.*, 1994; Beamish and Lavin, 1994; Khanna *et al.*, 1995; Barlow *et al.*, 1996; Xu and Baltimore, 1996). A-T cells exhibit deficient or severely delayed induction of p53 in response to IR (Kastan *et al.*, 1992; Khanna and Lavin, 1993; Lu and Lane, 1993; Xu and Baltimore, 1996). p53 mediated transcriptional activation of p21/WAF1/CIP1 and Gadd45, and the subsequent inhibition of G1 cyclin-dependent kinases, are also defective in A-T cells following IR exposure (Artuso *et al.*, 1995; Khanna *et al.*, 1995). Lu and Lane, 1993, however, reported very little difference in the p53 response from normal and A-T cells.

Furthermore, yeast have an ATM homologue (Mec-1) but do not have p53 (Goffeau *et al.*) The best data for a possible substrate for Mec-1p is spk1/Rad53 (Sun *et al*; Sanchez *et al.*)

The gene mutated in A-T patients, termed ATM (A-T mutated) has been mapped and its cDNA cloned (Savitsky *et al.*, 1995a; Savitsky *et al.*, 1995b). Sequence analyses reveal that the ATM gene encodes a ~350 kDa polypeptide that is a member of the phosphatidylinositol (PI) 3-kinase family

of proteins by virtue of a putative kinase domain in its carboxyl-terminal region (Savitsky *et al.*, 1995a; Savitsky *et al.*, 1995b). Classical PI 3-kinases, such as PI 3-kinase itself, are involved in signal transduction and phosphorylate inositol lipids that act as intracellular second messengers (reviewed in Kapeller and Cantley, 1994). ATM bears sequence similarity with a subset of the PI 3-kinase protein family that comprises proteins which, like ATM, are involved in cell cycle control and/or in the detection and signalling of DNA damage (for reviews see Hunter, 1995; Keith and Schreiber, 1995; Zakian, 1995; Jackson, 1996). Included in this sub-group are Saccharomyces cerevisiae Tor1p and Tor2p and their mammalian homologue FRAP, which control progression into S-phase and, at least in part, function by regulating translation (Brown and Schreiber, 1996). Also in this sub-group is the DNA dependent protein kinase (DNA-PK) catalytic subunit (DNA-PKcs), defects in which lead to sensitivity to IR and an inability to perform site-specific V(D)J recombination (reviewed in Jackson and Jeggo, 1995; Jackson, 1996) Other members of the ATM sub-group of the PI 3-kinase family that have been identified include S. cerevisiae Tel1p and Mec1p, together with the Mec1p homologues of Schizosaccharomyces pombe (rad3), Drosophila melanogaster (mei-41) and humans FRP1/ATR; (Keith and Schreiber, 1995; Zakian, 1995; Jackson, 1996). As with ATM, defects in these proteins lead to genomic instability, hypersensitivity towards DNA damaging

agents and defects in DNA damage-induced cell cycle checkpoint controls.

ATM is most similar to *S. cerevisiae* Tel1p, which has not been shown to have any biochemical function so far (identity and similarity are 45% and 66%, respectively). ATM is much further diverged from DNA-PKcs (28% identical and 51% similar), with essentially the same homology to PI 3-kinase (a *bona fide* lipid kinase: 24% identical and 51% similar). Thus, from the sequence comparisons alone, one could not predict that ATM would be a protein kinase akin to DNA-PKcs or a lipid kinase akin to P1 kinase.

Although genetic data indicate an involvement of ATM-like proteins in DNA damage recognition and its repair, the mechanisms by which these proteins function are not well understood. Much is known about the clinical symptoms and cellular phenotypes that arise from mutations in ATM, but little is known about the mechanisms by which the ATM protein functions. Recent studies have revealed that, like DNA-PKcs, ATM is expressed ubiquitously and is localised predominantly in the cell nucleus (Chen and Lee, 1996; Lakin *et al.*, 1996; Brown *et al.*, 1997; Watters *et al.*, 1997).

The realisation that ATM is a member of the PI 3-kinase family has suggested to some that the primary function of ATM might phosphorylate inositol phospholipids. Savitsky et al (1995 Science 268, 1749-1753), for example, do not discuss protein phosphorylation. Indeed, several lines of evidence suggest that ATM might have functioned in a very

different way from that which we have established herein. For example, defective protein tyrosine phosphorylation and calcium mobilization in response to the triggering of B-cells and T-cells of A-T patients support the idea of defects in intra-cytoplasmic signalling pathways in A-T cells (cited in the Savitski Science paper 1995). These data are provided in the paper Khanna et al (1997; J. Biol. Chem.). This paper also summarises a variety of other data suggesting different ways in which ATM might function.

Savitsky et al (Science 1995) state that the insulin-dependent diabetes observed in some A-T patients could reflect ATM acting in an analogous way to PI 3-kinase affecting glucose transport by insulin. They also discuss PI 3-kinase in terms of controlling apoptosis as a paradigm for ATM, ie. one can explain many of the features of A-T by suggesting that it works analogously to PI 3-kinase.

Some A-T cells have been shown to be complemented by a gene called ATDC, whose product interacts with an intermediate filament protein called vimentin, which is cytoplasmic (Brzoska et al; PNAS). They state that A-T cell lines have aberrantly aggregated actin filaments, suggesting the role of ATM lies in the cytoplasm.

We have purified ATM. We report that, in several respects, ATM is similar to DNA-PKcs. Thus, ATM binds to DNA and possesses an associated protein kinase activity that is stimulated by DNA. Furthermore, we show that ATM serves

as a kinase for p53 and that the sites of phosphorylation reside in functionally important regions of the p53 polypeptide. One site is at Ser 315. The other sites are Ser 15 and Thr18.

Ser315 is an unexpected site for phosphorylation by ATM. It has been shown previously to be phosphorylated by cyclin-dependent kinases and this has been shown to activate p53 DNA binding potential (Bischoff *et al.*). However, no cell cycle regulated p53 DNA binding potential has been observed. ATM may activate p53 DNA binding by targeting this site and, by targetting the other sites, cause disassociation of Mdm-2, thus stabilising p53 (leading to increased amounts of the protein) and would allow it to activate transcription.

Thr18 of p53 has to our knowledge never been shown to be phosphorylated *in vivo* or *in vitro*. This site does not conform to a characterized DNA-PK consensus phosphorylation site. Thus, our finding of phosphorylation here is totally unexpected.

Ser 15 is phosphorylated by DNA-PK, but nonetheless its phosphorylation by ATM is also surprising, particularly since there are no data indicating its phosphorylation in reponse to DNA damage being altered in A-T cells.

Based on this and other work described below, the present invention in various aspects provides for modulation of interaction between ATM and p53, particularly

phosphorylation of p53 by ATM, and ATM DNA binding, which is further shown to have a potentiating effect on phosphorylation of p53 by ATM.

Various aspects of the present invention provide for the use of ATM and p53, with or without DNA, in screening methods and assays for agents which modulate interaction between ATM and p53, particularly phosphorylation of p53 by ATM

Further aspects provide for modulation of interaction between ATM and other molecules including a phosphorylation site homologous to those in p53 which are phosphorylated by ATM, and use of these molecules in screening methods and assays for useful agents. For simplicity, much of the present disclosure refers to ATM and p53. However, unless the context requires otherwise, every such reference should be taken to be equally applicable to the interaction between ATM and other molecules including a site homologous to one of those in p53 phosphorylated by ATM.

Such molecules may be identified by various means. For instance, information may be obtained about residues which are important for p53 phosphorylation by ATM using alaline scanning and deletion analysis of p53 and/or peptide fragments, for instance the N-terminal 42 amino acids or so of p53, or a fragment of around 10 amino acids including the relevant site of phosphorylation. Mutation may be used to identify residues which affect phosphorylation and those which do not. When key residues are identified, computer

sequence databases may be scanned for proteins including the same or similar pattern of residues, taking into account conservative variation in sequence (see below) as appropriate. Candidate molecules may then be used in one or more assays for phosphorylation by ATM (such as discussed below).

Identification of key residues for phosphorylation at any of the sites in p53 phosphorylated by ATM may also be used in the design of peptide and non-peptidyl agents which modulate, particularly inhibit, phosphorylation of p53 by ATM, as discussed further below.

Methods of obtaining agents able to modulate interaction between ATM and p53 (or, it must be remembered, ATM and other molecules including a phosphorylation site homologous to one of those phosphorylated in p53 by ATM) include methods wherein a suitable end-point is used to assess interaction in the presence and absence of a test substance. Assay systems may be used to determine ATM kinase activity, ATM DNA binding and/or ATM interaction with one or more other molecules. For phosphorylation assays, full-length p53, truncated portions of p53, or portions of p53 fused to other proteins (eg. GST), or a suitable variant or derivative of any of these may be used. Peptide phosphorylation assays may be developed using peptides that correspond to the phosphorylated regions of p53. The phosphorylation of any of the above may be assayed by any of

a variety of procedures such as discussed below and may be adapted to high throughput screening approaches. Interference of DNA binding may be assayed but the inhibition of kinase activity may be more sensitive and identify a greater breadth of inhibitors to DNA binding inhibition, and so may be preferred by the skilled operator of the present invention.

ATM kinase activity may be assayed for the N-terminal p53 sites and/or for the C-terminal p53 site. When assaying for phosphorylation of the N-terminal sites, DNA is preferably included in the assay system. When assaying for phosphorylation of the C-terminal p53 site, DNA need not be included. Related but different screens may be set up for inhibitors and activators of the two types of ATM-mediated phosphorylation event.

Generally of most interest is modulation of the phosphorylation of p53 (or other molecule) by ATM. Detailed disclosure in this respect is included below. It is worth noting, however, that combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to modulate an interaction with and/or activity of a polypeptide. Such libraries and their use are known in the art, for all manner of natural products, small molecules and peptides, among others. The use of peptide libraries may be preferred in certain circumstances.

The ATM gene is mutated in human individuals with the autosomal recessive genetic disorder ataxia-telangiectasia (A-T). A-T is characterised by a variety of debilitating symptoms, including immune deficiencies, growth retardation, neurological deterioration, certain characteristics of premature ageing, and an approximately 100-fold increased incidence of lymphoreticular malignancies. At the cellular level, A-T cells display chromosomal instability, radiosensitivity, are impaired in p53 induction following treatment with ionising radiation, and show altered regulation of transcription factor NFkB. Thus, the wild-type ATM gene functions as a tumour suppressor, and is a suppressor of neurological degeneration and other degenerative states commonly associated with ageing.

Given the results reported herein on which the present invention is based, activators and inhibitors of ATM-associated kinase activity may be identified and appropriate agents may be obtained, designed and used for any of a variety of purposes:

A-T Therapy. Activators of ATM function may prove to have utility in treating humans with A-T (discussed further below).

Modulation of immune system function. A-T patients display immunodeficiencies, demonstrating that ATM is required for generation of a fully functional immune system. Modulators of ATM may, therefore, be used in regulating immune system function.

AIDS therapy. It has been shown that the lymphocytes of humans entering the final stages of AIDS have shortened telomeres and this may contribute to them being no longer able to replenish the immune system. Cells of A-T patients lose their telomeres more quickly than those of normal individuals, revealing that ATM plays a positive role in telomere length homeostasis. Activators of ATM function may, therefore, find utility in treatment of individuals with AIDS through lengthening the telomeres of senescent lymphocytes in these individuals, thus allowing replenishment of the immune system.

p53 therapy. The identification of the site of p53 phosphorylated by ATM indicates that this of extreme regulatory importance. Indeed, one of the sites on p53 phosphorylated by ATM resides within the region known as "conserved region I" that has been shown to interact with the protein Mdm-2 (see Kussie et al 1996; Picksley *et al.*, 1994; Momand *et al.*, 1992; Chen *et al.*, 1993 and references therein). Mdm-2 serves as a negative regulator of p53 by two mechanisms. First, it masks the p53 transcriptional activation domain, stopping p53 activating genes (Momand *et al.*, 1992). Second, Mdm-2 has been shown recently to target p53 for degradation within the cell (Kubbutat *et al.*, 1997; Haupt *et al.*, 1997). Our data therefore provide indication that phosphorylation of p53 by ATM will disrupt its interactions with Mdm-2, thus resulting in increased levels of transcriptionally active p53. This knowledge may,

therefore, be utilised to generate novel therapeutic agents that target p53 - such as small molecules that, through binding to mutant p53, mimic ATM-mediated activation of this molecule.

Phosphorylation at any one or more of these sites may affect interaction of p53 with a number of proteins. Mdm2 is one particularly example given the location of Thr18 within the site on p53 to which Mdm2 binds (see e.g. Chen *et al.*, (1993), Kussie *et al.*, (1996), Picksley *et al.*, (1994) and Momand *et al.*, (1992) for characterisation of this interaction). Phosphorylation of p53 may be used to affect interaction of p53 with any of a number of other proteins, including CBP (Gu *et al.*; Lill *et al.*), Adenovirus E1B protein, which binds within the amino terminal 123 amino acids of p53 (Kao *et al.*, 1990), with residues Leu-22 and Trp-23 playing an important role (Lin *et al.*, 1994), transcription factors XPD (Rad3) and XPB, as well as CSB involved in strand-specific DNA repair (Wang *et al.*, 1995). TFIIH (Xiao *et al.*, 1994), E2F1 and DP1 (O'Connor *et al.*, 1995), Cellular Replication Protein A (Li and Botchan, 1993), replication factor RPA (Dutta *et al.*, 1993), WT1 (Maheswaran *et al.*, 1993), TATA-binding protein (Seto *et al.*, 1992, Truant *et al.*, 1992, Martin *et al.*, 1993), and TAF(II)40 and TAF(II)60 (Thut *et al.*, 1995).

An assay according to the present invention as discussed further below may determine the role of phosphorylation of p53 by ATM on any of these interactions

and an agent found to be able to modulate such phosphorylation may be used to disrupt or promote any of these interactions, e.g. in a therapeutic context.

Modulating telomere length. A-T cells show accelerated rates of telomere shortening (Metcalfe et al., 1996, *Nature Genetics* 13, 350-353). Thus, regulators of ATM activity may be used to control telomere length. ATM does not appear to be part of the telomerease enzyme itself (Metcalfe *et al.* shows that telomerase levels are normal in A-T cells; also, our data and the data of Pandita *et al.* 1995 show that A-T cells have somewhat shortened telomeres but do not have repressed levels of telomerase). Thus, ATM works not as part of telomerase but as part of a telomere length homeostatic mechanism. It is therefore likely that anti-ATM drugs will work synergistically with anti-telomerase drugs.

Ageing. A-T patients display enhanced rates of ageing, display a number of symptoms associated with increased age (neurological deterioration, cancers, immunological deficiencies etc), and their cells show shortened lifespan in culture. Agents that modulate ATM activity may therefore be used to treat/prevent disease states associated with premature and normal ageing.

Tumour/Cancer therapy. This is discussed below.

Drugs that modulate ATM action may be used to treat A-T patients; treat cancer - through affecting cellular growth capacity by shortening cells telomeres; manipulate the

immune system - A-T patients are somewhat immunodeficient; treat cancer - radiosensitization of tumours etc (see below). Also, ATM modulators may be used to limit cell growth potential by affecting telomere length etc. The linkage to p53 may allow p53 therapy, activating p53 in cancer cells, which may lead to cell growth arrest and/or cell death via apoptosis or another route.

ATM activators may be used, for example, to inhibit cell proliferation by activating cell cycle checkpoint arrest in the absence of cellular damage, which may be used in the treatment of tumours, cancer, psoriasis, arteriosclerosis and other hyper-proliferative disorders. Activators may be employed to activate p53 in cells without damaging the cells. Cells of a patient may be treated so that normal cells (p53+) stop growing and are thus refractory to killing by administration of a drug that kills cells via interfering with cell division or DNA replication, while tumour cells (most of which are p53 negative) do not arrest and are consequently selectively killed by the aforementioned agents.

Cancer radiotherapy and chemotherapy may be augmented using agents in accordance with the present invention. Ionising radiation (IR) and radiomimetic drugs are used commonly to treat cancers, and kill cancer cells predominantly by inflicting DNA damage. Cells deficient in ATM are hypersensitive to ionising radiation and radiomimetics. Thus, inhibitors of the ATM will

hypersensitise cells to the killing effects of ionising radiation. ATM inhibitors may thus be used as adjuncts in cancer radiotherapy and chemotherapy.

Cell growth capacity may be modulated e.g. in treatment of cancer, ageing, and AIDS. It is established that ATM plays a crucial role in controlling the length of telomeric chromosomal ends (Metcalfe *et al.*). Telomeric ends in most normal cell types shorten at each cell division, and cells with excessively shortened telomeres are unable to divide. Thus, telomeres are thought to function as a "division counting apparatus" that limits the proliferative capacity of most normal mammalian cells. Inhibitors of ATM function may, therefore, have utility in preventing cancer progression by limiting the growth potential of cancerous or pre-cancerous cells. Activators of ATM may be used to release senescent cells from growth arrest and may thus have utility in treatments of aged individuals. In addition, it has been shown recently hat the lymphocytes of humans entering the final stages of AIDS have shortened telomeres and this may contribute to these cells being no longer able to proliferate and replenish the immune system. ATM activators may, therefore, result in lengthening of the telomeres of such cells and restoring their proliferative capacity.

Interaction between ATM and p53 may be inhibited by inhibition of the production of the relevant protein. For

instance, production of one or more of these components may be inhibited by using appropriate nucleic acid to influence expression by antisense regulation. The use of anti-sense genes or partial gene sequences to down-regulate gene expression is now well-established. Double-stranded DNA is placed under the control of a promoter in a "reverse orientation" such that transcription of the "anti-sense" strand of the DNA yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. The complementary anti-sense RNA sequence is thought then to bind with mRNA to form a duplex, inhibiting translation of the endogenous mRNA from the target gene into protein. Whether or not this is the actual mode of action is still uncertain. However, it is established fact that the technique works.

Another possibility is that nucleic acid is used which on transcription produces a ribozyme, able to cut nucleic acid at a specific site - thus also useful in influencing gene expression. Background references for ribozymes include Kashani-Sabet and Scanlon, 1995, *Cancer Gene Therapy*, 2(3): 213-223, and Mercola and Cohen, 1995, *Cancer Gene Therapy*, 2(1), 47-59.

Thus, various methods and uses of modulators, which inhibit or potentiate interaction of ATM and p53, particularly phosphorylation of p53 by ATM, are provided as further aspects of the present invention. The purpose of

disruption, interference with or modulation of interaction between ATM and p53, particularly the phosphorylation of p53 by ATM may be to modulate any activity mediated by virtue of such interaction, as discussed above and further below.

Various aspects of the present invention relate to modulation of interaction between ATM and DNA. Such interaction is established here we believe for the first time, and is further shown to have an effect on p53 phosphorylation by ATM. It was surprising that ATM is a DNA binding protein, as there are data suggesting that it is associated with microsomal membranes in the cytoplasm (Watters et al, 1997 and Brown et al, 1997; show ATM is also present in cytoplasmic vesicles) and A-T cells have also been reported to be defective in signalling from the cell membrane in B- and T-cells (see above). It was furthermore surprising that ATM would bind DNA so well. The purification method used and described below does not purify a variety of other (known) DNA binding factors, yet ATM is purified very selectively (about 100-fold in a single step) using a DNA affinity chromatography procedure.

The present invention provides in one aspect the use of DNA for purifying ATM. In further aspects, the present invention provides for the use of DNA in assays for activity of ATM, particularly phosphorylation of p53 (or other molecule).

We have also purified ATM via another surprising route, using nitrilo-tri-acetic acid (NTA) agarose. NTA has 4 chelating sites for Ni^{2+}. Another Ni^{2+} matrix, iminodiacetic acid (IDA) agarose (with 3 chelating sites for Ni^{2+}) we have found to bind ATM only weakly. These Ni^{2+} matrices are generally used interchangeably to purify proteins that chelate metal ions, usually, via a run of His residues (usually 6 give best binding). ATM does not have a run of 6, 5 or even 4 His residues, so it is surprising that ATM is purifiable by the Ni-linked columns. Furthermore, since the two matrices are generally used interchangeably, it is further surprising that ATM binds to the NTA well but only poorly to the IDA matrix.

ATM no doubt works in concert with other factors in the detection and signalling of DNA damage. Indeed, although our data reveal that ATM possesses intrinsic DNA-stimulated p53 kinase function, we have observed repeatedly that the presence of additional polypeptides correlates with increased ATM activity. Thus, our most highly purified preparations have considerably less activity than preparations containing an equivalent amount of ATM but also possessing additional co-purifying polypeptides. It is likely that these serve to help tether ATM to the DNA and/or trigger its kinase activity by altering the conformation of the ATM polypeptide.

Assays according to the present invention may be used

in the identification of such additional polypeptides, for example by assaying for protein fractions that stimulate ATM activity. The use of ATM in identifying and/or obtaining cofactors which (e.g. naturally) enhance its kinase activity is further provided by the present invention. ATM activity may under certain circumstances be masked by one or more factors (see discussion section below). Accordingly, the present invention also provides for the use of ATM in identifying and/or obtaining such factors.

Protein or other co-factors of ATM, e.g. which enhance ATM kinase activity, may be used in the design of inhibitors of this, providing another route for modulating ATM activity. This may similarly be used to provide a route to deriving agents that activate ATM, e.g. by inhibiting one or more repressors of ATM activity.

Brief Description of the Figures

Figure 1: ATM binds to DNA. (A) ATM binds to a dsDNA oligonucleotide. HeLa nuclear extract was bound to either streptavidin iron oxide beads (-DNA) or streptavidin iron oxide beads bearing a 50-mer ds DNA oligonucleotide (+DNA). After extensive washing, ATM was eluted from DNA in 500 mM KCl. Eluted proteins were subjected to 7% SDS-PAGE and ATM visualised by Western blotting using ATM.B antiserum. (B) Binding of ATM is dependent on DNA length. ATM enriched extract was bound to streptavidin iron oxide beads attached to ds DNA of various sizes (15, 25, 50 or 75 bp). After

extensive washing, ATM was eluted by sequential washes with 100, 250 and 500 mM KCl. Eluates were analysed as in (A). (C) ATM binds DNA containing a variety of different architectures. ATM enriched extract was bound to streptavidin iron oxide beads bound to either ss or ds DNA containing a nick, ds/ss transition, gap or 10 bp insertion. Washing, elution and ATM detection was as in (B).

Figure 2: Purification of ATM from HeLa cell nuclear extract. (A) ATM Purification strategy. HeLa nuclear extract was subjected to ion exchange chromatography using Q-Sepharose and peak ATM fractions, eluting between 160-200 mM KCl, were passed over heparin-agarose ion exchange resin. ATM fractions eluting from heparin-agarose between 200-220 mM KCl were pooled and subjected to DNA affinity purification and elution from DNA-bearing beads at 500 mM CK1 resulting in an essentially homogeneous preparation of ATM. (B) Purification of ATM to essential homogeneity. Equivalent volumes (5 μl) of HeLa cell nuclear extract (50 μg protein), or pooled fractions following Q-sepharose, Heparin-agarose or DNA affinity chromatography were subjected to 7% SDS-PAGE and proteins visualised by silver staining (upper panel). Fractions were also subjected to Western blot analysis (lower panel) using antibodies raised against ATM, DNA-PK_{CS}, Ku70 plus Ku80 or the 70kDa subunit of RPA, as indicated.

Figure 3: Purified ATM possesses an associated p53 kinase activity. (A) Analysis of putative ATM substrates.

DNA-PK_{CS} (60 ng), Ku (100 ng), Sp1 (100 ng), p53 (100 ng), RPA-p34 (100 ng) or PCNA (100 ng) were used in kinase reactions in conjunction with approximately 11 fmole of purified ATM (see Experimental Procedures). Proteins were resolved on either 7% (left panel) or 10% (right panel) polyacrylamide gels and phosphorylated proteins detected by autoradiography. (B) Analysis of total proteins immunoprecipitated from purified ATM preparations. Purified ATM was biotinylated and subjected to immunoprecipitation using either pre-immune sera, or ATM antisera raised against amino acid residues 1980-2337 (ATM.B) or the N-terminus (ATM.N) of ATM. Precipitated proteins were resolved on 7.8% polyacrylamide gels and, after transfer to nitrocellulose, total precipitated proteins were detected by probing filters with streptavidin-conjugated horseradish peroxidase. (C) Immunoprecipitated ATM possesses p53 kinase activity. Purified ATM was immunoprecipitated using pre-immune sera, or anti-ATM antisera ATM.B or ATM.N. Following immunoprecipitation, kinase reactions were performed either in the presence or absence of p53 as indicated. Phosphorylated proteins were resolved on 10% polyacrylamide gels and detected by autoradiography.

Figure 4: A DNA-stimulated protein kinase activity co-purifies with ATM. (A) ATM associated kinase activity is stimulated by linear DNA containing multiple p53 binding sites. Purified ATM, DNA-PK or cyclin A/cdk2 (11 fmole), as indicated, were used in kinase reactions containing p53

either in the absence (-) or presence of 0.03, 0.3 or 3 fmole of linear DNA bearing multiple p53 binding sites ($pG_{13}CAT$). Proteins were resolved on 10% polyacrylamide gels and phosphorylated proteins visualised by autoradiography. (B) ATM associated kinase activity does not require DNA ends. *In vitro* kinase reactions containing 11 fmole of purified ATM in conjunction with p53 were performed in either the absence (-) or presence of 0.03, 0.3 or 30 fmole of linear or supercoiled $pG_{13}CAT$ DNA. Proteins were detected as in (A).

Figure 5: ATM associated kinase activity is not affected by classical P I-3 kinase inhibitors. (A) ATM associated kinase activity is not inhibited by wortmannin. *In vitro* kinase assays using equimolar amounts of purified ATM or DNA-PK (11 fmole), as indicated, were performed in conjunction with p53 either in the absence (-) or presence of 125, 250, 500 or 1000 nM of wortmannin. Phosphorylated proteins were resolved on 10% polyacrylamide gels and visualised by autoradiography. (B) Immunoprecipitated ATM associated kinase activity is not inhibited by wortmannin. Purified ATM protein was immunoprecipitated using either pre-immune or anti-ATM antiserum. Immunoprecipitates were then used in kinase assays in conjunction with p53 either in the absence (-) or presence of 125, 250, 500 or 1000 nM wortmannin. Phosphorylated proteins were detected as in (A). (C) ATM associated kinase activity is not inhibited by LY294002. *In vitro* kinase assays using equimolar amounts of

purified ATM or DNA-PK (11 fmole) were performed in conjunction with p53 in either the absence or presence of 0.1, 0.5, 1, 2.5, 5 and 50 μM LY294002. Phosphorylated proteins were detected as in (A).

Figure 6: ATM phosphorylates p53 constitutively at Ser-315 and at Ser-15 and thr-18 in the presence of DNA. (A) Tryptic peptide map of p53 phosphorylated with ATM in the absence of DNA. Kinase reactions containing ATM and p53 were performed in the absence of DNA and bands corresponding to ^{32}P-labelled p53 were excised from a gel, digested with trypsin, and chromatographed on a Vydac 218TP54 C18 column (see Experimental Procedures). (B) Sequence analysis of p53 phosphorylation in the absence of DNA. Purified peak fractions of peptide 1a were subjected to peptide sequence analysis as described in Experimental Procedures; radioactivity was measured after each cycle of Edman degradation. The putative amino acid sequence of the peptide is indicated below the graph. (C) Tryptic peptide map of p53 phosphorylated with ATM in the presence of DNA. Kinase reactions containing ATM and p53 were performed in the presence of supercoiled DNA, and ^{32}P-labelled p53 was analysed as in (A). (D) Tryptic peptide map of p53 phosphorylated by DNA-PK in the presence of DNA. Kinase reactions containing DNA-PK and p53 were performed in the presence of linear DNA and ^{32}P-labelled p53 was analysed as in (A). (E) Sequence analysis of p53 phosphorylated by ATM preparations in the presence of DNA. Purified peak

fractions of peptide 2a from panel (C) were subjected to peptide sequence analysis as described in (B).

Figure 7: ATM-associated kinase activity is not affected markedly by inhibitors of cyclin dependent protein kinases. (A) ATM associated kinase activity is not inhibited by p21. *In vitro* kinase assays using equimolar amounts of purified cyclin A/cdk2 or ATM (11 fmole) were performed in conjunction with p53 either in the absence (-) or presence of 0.125, 1.25 or 12.5 ng of recombinant p21. Phosphorylated proteins were resolved on 10% polyacrylamide gels and were visualised by autoradiography. (B) ATM-associated kinase activity is not inhibited by the cyclin dependent protein kinase inhibitor roscovitin. *In vitro* kinase assays using equimolar amounts of either purified cyclin A/cdk2 or ATM (11 fmole) were performed in conjunction with p53 in either the absence or presence of 1, 5, 10 or 100 μM roscovitin. Phosphorylated proteins were analysed as in (A).

Figure 8 shows the amino acid sequence of human ATM, with the kinase domain marked.

Figure 9 shows the amino acid sequence of human p53 with residues phosphorylted by ATM marked.

The present invention in various aspects provides for modulating, interfering with or interrupting, increasing or potentiating interacion between the ATM protein and p53, particularly phosphorylation of p53 by ATM, using an appropriate agent. As noted, it having now been established

for the first time that ATM is a protein kinase, it is highly likely to act on other molecules, particularly proteins including a site which is homologous to one of the sites in p53 phosphorylated by ATM. The present invention extends to modulation of such phosphorylation and this should be borne in mind when considering the disclosure herein which for convenience uses p53 for illustrative purposes, and as a preferred embodiment in certain contexts.

An agent capable of modulating interaction between ATM and p53 may be capable of blocking interaction between a site located within amino acid residues including Ser15, Thr18 or Ser 315.

In addition to interacting at the site of phosphorylation of p53, ATM and p53 may interact at one or more other sites within either or both proteins. Affecting interaction at such a site may have an effect on phosphorylation of p53 by ATM. Various fragments and derivatives of the proteins, particular of p53, may be used to analyse this, using techniques such as alanine scanning and deletion analysis. The present invention encompasses modulation of interaction between ATM and p53 at any site, preferably resulting in modulation of p53 phosphorylation by ATM.

The full amino acid sequence of the ATM protein has been elucidated and is set out in Savitsky *et al* 1995a, 1995b, and Figure 8,of which the amino acid residue

numbering is used. The kinase domain is marked in Figure 8. The p53 amino acid sequence is shown in Figure 9, of which the amino acid residue numbering is used. These sequences are human sequences. ATM and p53 are conserved among vertebrates, particular mammals - see e.g. Figure 2 of Soussi *et al*. For p53 conservation in the regions of the residues shown herein to be phosphorylated by ATM - so the present invention extends to use in any of its aspects of other vertebrate, particularly mammalian, p53 and/or ATM, e.g. primate, such as monkey, rodent, such as mouse or rat, pig, horse, cow, sheep, goat, dog, cat, and so on.

Agents useful in accordance with the present invention may be identified by screening techniques which involve determining whether an agent under test inhibits or disrupts the interaction of ATM protein or a suitable fragment thereof (e.g. including amino acid residues of the kinase domain, as marked on Figure 8, or a smaller fragment of any of these regions) of ATM, with p53 or a fragment thereof, or a suitable analogue, fragment or variant thereof.

Suitable fragments of ATM or p53 include those which include residues which interact with the counterpart protein. Smaller fragments, and analogues and variants of this fragment may similarly be employed, e.g. as identified using techniques such as deletion analysis or alanine scanning.

Thus, the present invention provides a peptide fragment

of ATM which is able to interact with p53 and/or inhibit interaction between ATM and p53, particularly phosphorylation of p53 by ATM, and provides a peptide fragment of p53 which is able to interact with ATM and/or inhibit interaction between p53 and ATM, particularly phosphorylation of p53 by ATM, such peptide fragments being obtainable by means of deletion analysis and/or alanine scanning of the relevant protein - making an appropriate mutation in sequence, bringing together a mutated fragment of one of the proteins with the other or a fragment thereof and determining interaction, preferably phosphorylation of p53 or fragment thereof. In preferred embodiments, the peptide is short, as discussed below, and may be a minimal portion that is able to interact with the relevant counterpart protein and/or inhibit the relevant interaction.

Screening methods and assays are discussed in further detail below.

One class of agents that can be used to disrupt the interaction of ATM and p53 are peptides based on the sequence motifs of ATM or p53 that interact with counterpart p53 or ATM (as discussed already above). Such peptides tend to be short, and may be about 40 amino acids in length or less, preferably about 35 amino acids in length or less, more preferably about 30 amino acids in length, or less, more preferably about 25 amino acids or less, more

preferably about 20 amino acids or less, more preferably about 15 amino acids or less, more preferably about 10 amino acids or less, or 9, 8, 7, 6, 5 or less in length. The present invention also encompasses peptides which are sequence variants or derivatives of a wild type ATM or p53 sequence, but which retain ability to interact with p53 or ATM (respectively, as the case may be) and/or ability to modulate interaction between ATM and p53, particularly phosphorylation of p53 by ATM.

Instead of using a wild-type ATM or p53 fragment, a peptide or polypeptide may include an amino acid sequence which differs by one or more amino acid residues from the wild-type amino acid sequence, by one or more of addition, insertion, deletion and substitution of one or more amino acids. Thus, variants, derivatives, alleles, mutants and homologues, e.g. from other organisms, are included.

Preferably, the amino acid sequence shares homology with a fragment of the relevant ATM or p53 fragment sequence shown preferably at least about 30%, or 40%, or 50%, or 60%, or 70%, or 75%, or 80%, or 85%, 90% or 95% homology. Thus, a peptide fragment of ATM or p53 may include 1, 2, 3, 4, 5, greater than 5, or greater than 10 amino acid alterations such as substitutions with respect to the wild-type sequence.

A derivative of a peptide for which the specific sequence is disclosed herein may be in certain embodiments the same length or shorter than the specific peptide. In

other embodiments the peptide sequence or a variant thereof may be included in a larger peptide, as discussed above, which may or may not include an additional portion of ATM or p53. 1, 2, 3, 4 or 5 or more additional amino acids, adjacent to the relevant specific peptide fragment in ATM or p53, or heterologous thereto may be included at one end or both ends of the peptide.

(It should not be forgotten that references to ATM and p53 apply equally to ATM and other proteins including a phosphorylation site homologous to one in p53 phosphorylated by ATM.)

As is well-understood, homology at the amino acid level is generally in terms of amino acid similarity or identity. Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. Similarity may be as defined and determined by the TBLASTN program, of Altschul *et al.* (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art. Homology may be over the full-length of the relevant peptide or over a contiguous sequence of about 5, 10, 15, 20, 25, 30, 35, 50, 75, 100 or more amino acids, compared with the relevant wild-type amino acid sequence.

As noted, variant peptide sequences and peptide and non-peptide analogues and mimetics may be employed, as

discussed further below.

Various aspects of the present invention provide a substance, which may be a single molecule or a composition including two or more components, which includes a peptide fragment of ATM or p53 which includes a sequence as recited in Figure 8 or Figure 9, particularly within the ATM kinase domain marked in Figure 8, a peptide consisting essentially of such a sequence, a peptide including a variant, derivative or analogue sequence, or a non-peptide analogue or mimetic which has the ability to interact with ATM or p53 and/or modulate, disrupt or interfere with interaction between ATM or p53.

Variants include peptides in which individual amino acids can be substituted by other amino acids which are closely related as is understood in the art and indicated above.

Non-peptide mimetics of peptides are discussed further below.

As noted, a peptide according to the present invention and for use in various aspects of the present invention may include or consist essentially of a fragment of ATM or p53 as disclosed, such as a fragment whose sequence is shown in Figure 8 or Figure 9, respectively. Where one or more additional amino acids are included, such amino acids may be from ATM or p53 or may be heterologous or foreign to ATM or p53. A peptide may also be included within a larger fusion

protein, particularly where the peptide is fused to a non-ATM or p53 (i.e. heterologous or foreign) sequence, such as a polypeptide or protein domain.

The invention also includes derivatives of the peptides, including the peptide linked to a coupling partner, e.g. an effector molecule, a label, a drug, a toxin and/or a carrier or transport molecule, and/or a targeting molecule such as an antibody or binding fragment thereof or other ligand. Techniques for coupling the peptides of the invention to both peptidyl and non-peptidyl coupling partners are well known in the art. In one embodiment, the carrier molecule is a 16 aa peptide sequence derived from the homeodomain of *Antennapedia* (e.g. as sold under the name "Penetratin"), which can be coupled to a peptide via a terminal Cys residue. The "Penetratin" molecule and its properties are described in WO 91/18981.

Peptides may be generated wholly or partly by chemical synthesis. The compounds of the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California), or they may be

prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

Another convenient way of producing a peptidyl molecule according to the present invention (peptide or polypeptide) is to express nucleic acid encoding it, by use of nucleic acid in an expression system.

Accordingly the present invention also provides in various aspects nucleic acid encoding the polypeptides and peptides of the invention.

Generally, nucleic acid according to the present invention is provided as an isolate, in isolated and/or purified form, or free or substantially free of material with which it is naturally associated, such as free or substantially free of nucleic acid flanking the gene in the human genome, except possibly one or more regulatory sequence(s) for expression. Nucleic acid may be wholly or partially synthetic and may include genomic DNA, cDNA or RNA. Where nucleic acid according to the invention includes RNA, reference to the sequence shown should be construed as reference to the RNA equivalent, with U substituted for T.

Nucleic acid sequences encoding a polypeptide or

peptide in accordance with the present invention can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al, Short Protocols in Molecular Biology, John Wiley and Sons, 1992), given the nucleic acid sequence and clones available. These techniques include (i) the use of the polymerase chain reaction (PCR) to amplify samples of such nucleic acid, e.g. from genomic sources, (ii) chemical synthesis, or (iii) preparing cDNA sequences. DNA encoding ATM or p53 fragments may be generated and used in any suitable way known to those of skill in the art, including by taking encoding DNA, identifying suitable restriction enzyme recognition sites either side of the portion to be expressed, and cutting out said portion from the DNA. The portion may then be operably linked to a suitable promoter in a standard commercially available expression system. Another recombinant approach is to amplify the relevant portion of the DNA with suitable PCR primers. Modifications to the ATM or p53 sequences can be made, e.g. using site directed mutagenesis, to lead to the expression of modified ATM or p53 peptide or to take account of codon preference in the host cells used to express the nucleic acid.

In order to obtain expression of the nucleic acid

sequences, the sequences can be incorporated in a vector having one or more control sequences operably linked to the nucleic acid to control its expression. The vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted nucleic acid, nucleic acid sequences so that the polypeptide or peptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide produced in the host cell is secreted from the cell. Polypeptide can then be obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the polypeptide is produced and recovering the polypeptide from the host cells or the surrounding medium. Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.

Thus, the present invention also encompasses a method of making a polypeptide or peptide (as disclosed), the method including expression from nucleic acid encoding the polypeptide or peptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the polypeptide. Polypeptides and peptides may also be expressed in in vitro systems, such as reticulocyte lysate.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable

host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. A common, preferred bacterial host is E. coli.

Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook *et al.*, 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel *et al.* eds., John Wiley & Sons, 1992.

Thus, a further aspect of the present invention provides a host cell containing heterologous nucleic acid as disclosed herein.

The nucleic acid of the invention may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which

promote recombination with the genome, in accordance with standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell, or otherwise identifiably heterologous or foreign to the cell.

A still further aspect provides a method which includes introducing the nucleic acid into a host cell. The introduction, which may (particularly for *in vitro* introduction) be generally referred to without limitation as "transformation", may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage. As an alternative, direct injection of the nucleic acid could be employed.

Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as is well known in the art.

The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that

the encoded polypeptide (or peptide) is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium. Following production by expression, a polypeptide or peptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below).

Introduction of nucleic acid encoding a peptidyl molecule according to the present invention may take place in vivo by way of gene therapy, to disrupt or interfere with interaction between ATM or p53

Thus, a host cell containing nucleic acid according to the present invention, e.g. as a result of introduction of the nucleic acid into the cell or into an ancestor of the cell and/or genetic alteration of the sequence endogenous to the cell or ancestor (which introduction or alteration may take place in vivo or ex vivo), may be comprised (e.g. in the soma) within an organism which is an animal, particularly a mammal, which may be human or non-human, such as rabbit, guinea pig, rat, mouse or other rodent, cat, dog, pig, sheep, goat, cattle or horse, or which is a bird, such as a chicken. Genetically modified or transgenic animals or

birds comprising such a cell are also provided as further aspects of the present invention.

This may have a therapeutic aim. (Gene therapy is discussed below.) Also, the presence of a mutant, allele, derivative or variant sequence within cells of an organism, particularly when in place of a homologous endogenous sequence, may allow the organism to be used as a model in testing and/or studying substances which modulate activity of the encoded polypeptide *in vitro* or are otherwise indicated to be of therapeutic potential. Knock-out mice, for instance, may be used to test for radiosensitivity. Conveniently, however, at least preliminary assays for such substances may be carried out *in vitro*, that is within host cells or in cell-free systems. Where an effect of a test compound is established on cells *in vitro*, those cells or cells of the same or similar type may be grafted into an appropriate host animal for *in vivo* testing.

For instance, p53 function or activity may be measured in an animal system such as a tumour model, e.g. involving a xenograft, relying on active p53. The animal may be subject to radio- or chemo-therapy and a test substance administered. An augmentation of the reaction in the animal to the radio- or chemo-therapy may be indicative of blocking of ATM phosphorylation of p53.

Suitable screening methods are conventional in the art. They include techniques such as radioimmunosassay,

scintillation proximetry assay and ELISA methods. Suitably either the ATM protein or fragment or p53 or fragment, or an analogue, derivative, variant or functional mimetic thereof, is immobilised whereupon the other is applied in the presence of the agents under test. In a scintillation proximetry assay a biotinylated protein fragment may be bound to streptavidin coated scintillant - impregnated beads (produced by Amersham). Binding of radiolabelled peptide is then measured by determination of radioactivity induced scintillation as the radioactive peptide binds to the immobilized fragment. Agents which intercept this are thus inhibitors of the interaction. Further ways and means of screening for agents which modulate interaction between ATM and p53 are discussed below.

In one general aspect, the present invention provides an assay method for a substance with ability to modulate, e.g. disrupt or interfere with interaction between ATM and p53, the method including:

(a) bringing into contact a substance according to the invention including a peptide fragment of ATM or a derivative, variant or analogue thereof as disclosed, a substance including the relevant fragment of p53 or a variant, derivative or analogue thereof.

A test compound which disrupts, reduces, interferes with or wholly or partially abolishes interaction between said substances (e.g. including a ATM fragment and including

a p53 fragment), and which may modulate ATM and/or p53 activity, may thus be identified.

Agents which increase or potentiate interaction between the two substances may be identified using conditions which, in the absence of a positively-testing agent, prevent the substances interacting.

Another general aspect of the present invention provides an assay method for a substance able to interact with the relevant region of ATM or p53 as the case may be, the method including:

(a) bringing into contact a substance which includes a peptide fragment of ATM which interacts with p53 as disclosed, or which includes a peptide fragment of p53 which interacts with ATM, or a variant, derivative or analogue of such peptide fragment, as disclosed, and a test compound; and

(b) determining interaction between said substance and the test compound.

A test compound found to interact with the relevant portion of ATM may be tested for ability to modulate, e.g. disrupt or interfere with, ATM interaction with p53 and/or ability to affect p53 and/or ATM activity or other activity mediated by ATM or p53 as discussed already above.

Similarly, a test compound found to interact with the relevant portion of p53 may be tested for abiliy to modulate, e.g. disrupt or interfere with, p53 interaction with ATM and/or ability to affect ATM and/or p53 activity or

other activity mediated by p53 or ATM as discussed elsewhere herein.

Another general aspect of the present invention provides an assay method for a substance able to affect p53 activity, the method including:

(a) bringing into contact p53 and a test compound; and

(b) determining p53 activity.

p53 activity may be determined in the presence and absence of ATM to allow for an effect of a test compound on activity to be attributed to an effect on interaction between p53 and ATM, preferably phosphorylation of p53 by ATM (discussed further below).

p53 activities which may be determined include induction of expression of a protein such as p21 (WAF1), cellular sensitivity to ionizing radiation, p53-induced apoptosis activity, p53-induced anti-proliferative activity, p53-induced senescence of cells

In assaying for agents able to modulate phosphorylation of p53 by ATM, suitable fragments of p53 may be employed including any of the sites of such phosphorylation. Where it is desired to determine phosphorylation at the Ser15 and/or Thr18 site, DNA will generally be included in the assay system to stimulate the requisite kinase activity of ATM. Where it is desired to determine phosphorylation at the Ser315 site, DNA need not be included in the assay

system. (As noted, the present invention extends also to non-human p53 and phosphorylation at sites equivalent to those of human p53 identified herein.)

The present invention further provides the use of DNA for stimulating phosphorylation of p53 by ATM, e.g. in an assay but also in many other contexts. Such phosphorylation may include at the Ser15 and/or Thr18 site of human p53 or equivalent site in p53 of another species, particularly of a vertebrate such as a mammal.

An assay according to the present invention may include an inhibitor of DNA-PKcs kinase activity, to avoid complications of redundant phosphorylation by that kinase. Such an inhibitor of DNA-PKcs kinase activity may not affect ATM kinase activity. Preferred such inhibitors may include wortmannin and LY294002 (discussed further below).

Further assays according to the present invention are for agents which modulate DNA binding by ATM. Inhibitors and/or activators may be screened using appropriate conditions for determination of DNA binding by ATM.

Thus, a further aspect of the present invention provides an assay method for a compound able to affect DNA binding by ATM, the method including:

(a) bringing into contact a substance which is ATM or a fragment, variant or derivative thereof able to bind DNA, DNA and a test compound, under conditions wherein, in the

absence of the test compound being an inhibitor of DNA binding by ATM, said substance binds said DNA; and

(b) determining binding between said substance and said DNA.

Activators of DNA binding by ATM may similarly be identified using an assay method wherein said substance, the DNA and the test compound are brought together under conditions wherein in the absence of the test compound being a potentiator of DNA binding by ATM, the substance does not bind the DNA.

DNA binding may be determined using any suitable technique, including an electrophoretic mobility shift assay (EMSA), UV protein-DNA crosslinking, chemical or DNaseI footprinting, and so on.

Determination of DNA binding by ATM may be performed in conjunction with determination of phosphorylation, sequentially or simultaneously. For instance a preliminary screen may identify molecules which modulate DNA binding by ATM and such substances may then be used in assays to determine their ability (or not) to modulate phosphorylation of p53. The converse, in which ability to modulate phosphorylation is determined prior to ability to modulate ATM DNA binding, is also possible, as is to run two assays in parallel.

Preliminary assays *in vitro* may be followed by, or run in parallel with, *in vivo* assays.

Of course, the person skilled in the art will design any appropriate control experiments with which to compare results obtained in test assays.

Performance of an assay method according to the present invention may be followed by isolation and/or manufacture and/or use of a compound, substance or molecule which tests positive for ability to modulate interaction between ATM and p53 and/or inhibit ATM or p53 activity or a mediated activity.

The precise format of an assay of the invention may be varied by those of skill in the art using routine skill and knowledge. For example, interaction between substances may be studied *in vitro* by labelling one with a detectable label and bringing it into contact with the other which has been immobilised on a solid support. Suitable detectable labels, especially for peptidyl substances include ^{35}S-methionine which may be incorporated into recombinantly produced peptides and polypeptides. Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody.

The protein which is immobilized on a solid support may be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known *per se*. A preferred *in vitro* interaction may utilise a

fusion protein including glutathione-S-transferase (GST). This may be immobilized on glutathione agarose beads. In an *in vitro* assay format of the type described above a test compound can be assayed by determining its ability to diminish the amount of labelled peptide or polypeptide which binds to the immobilized GST-fusion polypeptide. This may be determined by fractionating the glutathione-agarose beads by SDS-polyacrylamide gel electrophoresis. Alternatively, the beads may be rinsed to remove unbound protein and the amount of protein which has bound can be determined by counting the amount of label present in, for example, a suitable scintillation counter.

An assay according to the present invention may also take the form of an *in vivo* assay. The *in vivo* assay may be performed in a cell line such as a yeast strain or mammalian cell line in which the relevant polypeptides or peptides are expressed from one or more vectors introduced into the cell.

The ability of a test compound to modulate interaction between ATM and p53 may be determined using a so-called two-hybrid assay.

For example, a polypeptide or peptide containing a fragment of ATM or p53 as the case may be, or a peptidyl analogue or variant thereof as disclosed, may be fused to a DNA binding domain such as that of the yeast transcription factor GAL 4. (A particularly preferred fragment of ATM may include or be the kinase domain or a fragment of the kinase domain.) The GAL 4 transcription factor includes two

functional domains. These domains are the DNA binding domain (GAL4DBD) and the GAL4 transcriptional activation domain (GAL4TAD). By fusing one polypeptide or peptide to one of those domains and another polypeptide or peptide to the respective counterpart, a functional GAL 4 transcription factor is restored only when two polypeptides or peptides of interest interact. Thus, interaction of the polypeptides or peptides may be measured by the use of a reporter gene probably linked to a GAL 4 DNA binding site which is capable of activating transcription of said reporter gene. This assay format is described by Fields and Song, 1989, Nature 340; 245-246. This type of assay format can be used in both mammalian cells and in yeast. Other combinations of DNA binding domain and transcriptional activation domain are available in the art and may be preferred, such as the LexA DNA binding domain and the VP60 transcriptional activation domain.

When looking for peptides or other substances which interfere with interaction between a ATM polypeptide or peptide and p53 polypeptide or peptide, the ATM or p53 polypeptide or peptide may be employed as a fusion with (e.g.) the LexA DNA binding domain, and the counterpart p53 or ATM polypeptide or peptide as a fusion with (e.g.) VP60, and involves a third expression cassette, which may be on a separate expression vector, from which a peptide or a library of peptides of diverse and/or random sequence may be expressed. A reduction in reporter gene expression (e.g. in

the case of β-galactosidase a weakening of the blue colour) results from the presence of a peptide which disrupts the ATM/p53 interaction, which interaction is required for transcriptional activation of the β-galactosidase gene. Where a test substance is not peptidyl and may not be expressed from encoding nucleic acid within a said third expression cassette, a similar system may be employed with the test substance supplied exogenously.

When performing a two hybrid assay to look for substances which interfere with the interaction between two polypeptides or peptides it may be preferred to use mammalian cells instead of yeast cells. The same principles apply and appropriate methods are well known to those skilled in the art.

In preferred assays according to the present invention, the end-point of the assay, that is to say that which is determined in order to assess the effect of the test agent on the interaction of interest, is phosphorylation of p53 or a fragment, variant or derivative thereof, or other molecule including a phosphorylation site homologous to one of those in p53 phosphorylated by ATM.

Thus, a further aspect of the present invention provides an assay method including

(a) bringing into contact a substance which includes at least a fragment of ATM which phosphorylates p53, a substance which includes at least a fragment of p53

including a site phosphorylated by ATM, and a test compound; and

(b) determining phosphorylation at said site.

Of course, any suitable variant or derivative of ATM and/or p53 may be employed in such an assay.

Phosphorylation may be determined for example by immobilising p53 or a fragment, variant or derivative thereof, e.g. on a bead or plate, and detecting phosphorylation using an antibody or other binding molecule (such as Mdm2 or a fragment thereof) which binds the relevant site of phosphorylation with a different affinity when the site is phosphorylated from when the site is not phosphorylated. Such antibodies may be obtained by means of any standard technique as discussed elsewhere herein, e.g. using a phosphorylated peptide (such as a fragment of p53). Binding of a binding molecule which discriminates between the phosphorylated and non-phosphorylated form of p53 or relevant fragment, variant or derivative thereof may be assessed using any technique available to those skilled in the art, which may involve determination of the presence of a suitable label, such as fluorescence. Phosphorylation may be determined by immobilisation of p53 or a fragment, variant or derivative thereof, on a suitable substrate such as a bead or plate, wherein the substrate is impregnated with scintillant, such as in a standard scintillation proximetry assay, with phosphorylation being determined via measurement of the incorporation of radioactive phosphate.

Phosphate incorporation into p53 or a fragment, variant or derivative thereof, may be determined by precipitation with acid, such as trichloroacetic acid, and collection of the precipitate on a nitrocellulose filter paper, followed by measurement of incorporation of radiolabeled phosphate.

An agent able to inhibit phosphorylation of p53 by ATM may include an ATP analogue or other substance able to affect the catalytic properties of the enzymically active site of ATM. An inhibitor of phosphorylation may interact with ATM within the kinase domain marked (for human ATM) in Figure 8. Residues within this domain are involved with interaction with p53 and catalysis of the phosphorylation. Residues outside of the domain may also be involved in interacting with p53 and agents which interfere with such interaction may affect the phosphorylation as discussed elsewhere herein.

The amount of test substance or compound which may be added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.001 nM to 1mM or more concentrations of putative inhibitor compound may be used, for example from 0.01 nM to 100μM, e.g. 0.1 to 50 μM, such as about 10 μM. Greater concentrations may be used when a peptide is the test substance. Even a molecule which has a weak effect may be a useful lead compound for further investigation and development.

Compounds which may be used may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used.

Antibodies directed to the site of interaction in either protein form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof which are responsible for disrupting the interaction.

Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage *et al.*, 1992, Nature 357: 80-82). Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of sacrificing the animal.

As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda

bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimicks that of an antibody enabling it to bind an antigen or epitope.

Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')2 fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

A hybridoma producing a monoclonal antibody according

to the present invention may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP184187A, GB 2188638A or EP-A-0239400. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.

The reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage

of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule. The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

Antibodies may also be used in purifying and/or isolating a polypeptide or peptide according to the present invention, for instance following production of the polypeptide or peptide by expression from encoding nucleic acid therefor. Antibodies may be useful in a therapeutic context (which may include prophylaxis) to disrupt ATM/p53 interaction with a view to inhibiting their activity. Antibodies can for instance be micro-injected into cells, e.g. at a tumour site, subject to radio- and/or chemo-therapy (as discussed already above). Antibodies may be employed in accordance with the present invention for other therapeutic and non-therapeutic purposes which are discussed elsewhere herein.

Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment and using rational drug design to provide potential inhibitor compounds with particular molecular shape, size and charge characteristics.

A compound found to have the ability to affect ATM and/or p53 activity has therapeutic and other potential in a number of contexts, as discussed. For therapeutic treatment such a compound may be used in combination with any other active substance, e.g. for anti-tumour therapy another anti-tumour compound or therapy, such as radiotherapy or chemotherapy. In such a case, the assay of the invention, when conducted *in vivo*, need not measure the degree of modulation of interaction between p53 and ATM (or appropriate fragment, variant or derivative thereof) or of modulation of p53 phosphorylation or activity caused by the compound being tested. Instead the effect on DNA repair, homologous recombination, cell viability, cell killing (e.g. in the presence and absence of radio- and/or chemo-therapy), retroviral integration, and so on, may be measured. It may be that such a modified assay is run in parallel with or subsequent to the main assay of the invention in order to confirm that any such effect is as a result of the inhibition of interaction between ATM and p53 caused by said inhibitor compound and not merely a general toxic effect.

Thus, an agent identified using one or more primary screens (e.g. in a cell-free system) as having ability to interact with ATM and/or p53 and/or modulate activity of ATM and/or p53 may be assessed further using one or more secondary screens. A secondary screen may involve testing for cellular radiosensitisation and/or sensitisation to radiomimetic drugs, effect on chromosome telomere length,

inducing or preventing cell-cycle arrest following irradiation or other cellular insult, an effect of p53 induction following ionising radiation or other cellular insult, or induction of p21 or other downstream p53 target.

Following identification of a substance or agent which modulates or affects ATM and/or p53 activity, the substance or agent may be investigated further. Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals, e.g. for any of the purposes discussed elsewhere herein.

As noted, the agent may be peptidyl, e.g. a peptide which includes a sequence as recited above, or may be a functional analogue of such a peptide.

As used herein, the expression "functional analogue" relates to peptide variants or organic compounds having the same functional activity as the peptide in question, which may interfere with the interaction between ATM and p53. Examples of such analogues include chemical compounds which are modelled to resemble the three dimensional structure of the ATM or p53 domain in the contact area, and in particular the arrangement of the key amino acid residues as they appear in ATM or p53.

In a further aspect, the present invention provides the

use of the above substances in methods of designing or screening for mimetics of the substances.

Accordingly, the present invention provides a method of designing mimetics of ATM or p53 having the biological activity of p53 or ATM binding or inhibition, the activity of allosteric inhibition of p53 or ATM and/or the activity of modulating, e.g. inhibiting, ATM/p53 interaction, said method comprising:

(i) analysing a substance having the biological activity to determine the amino acid residues essential and important for the activity to define a pharmacophore; and,

(ii) modelling the pharmacophore to design and/or screen candidate mimetics having the biological activity.

Suitable modelling techniques are known in the art. This includes the design of so-called "mimetics" which involves the study of the functional interactions fluorogenic oligonucleotide the molecules and the design of compounds which contain functional groups arranged in such a manner that they could reproduced those interactions.

The designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides are not well suited as active agents for oral compositions as they

tend to be quickly degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing may be used to avoid randomly screening large number of molecules for a target property.

There are several steps commonly taken in the design of a mimetic from a compound having a given target property. Firstly, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn. These parts or residues constituting the active region of the compound are known as its "pharmacophore".

Once the pharmacophore has been found, its structure is modelled to according its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process.

In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this the design of the mimetic.

A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade *in vivo*, while retaining the biological activity of the lead compound. The mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for *in vivo* or clinical testing.

The mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for *in vivo* or clinical testing.

Mimetics of this type together with their use in therapy form a further aspect of the invention.

The present invention further provides the use of a peptide which includes a sequence as disclosed, or a derivative, active portion, analogue, variant or mimetic, thereof able to interact with ATM or p53 and/or modulate, e.g. inhibit, interaction between ATM and p53 and/or modulate, e.g inhibit, ATM and/or p53 activity, in screening

for a substance able to interact with p53 and/or ATM, and/or modulate, e.g. inhibit, interaction between ATM and p53, and/or inhibit ATM and/or p53 activity.

Generally, such a substance, e.g. inhibitor, according to the present invention is provided in an isolated and/or purified form, i.e. substantially pure. This may include being in a composition where it represents at least about 90% active ingredient, more preferably at least about 95%, more preferably at least about 98%. Such a composition may, however, include inert carrier materials or other pharmaceutically and physiologicaly acceptable excipients. As noted below, a composition according to the present invention may include in addition to an inhibitor compound as disclosed, one or more other molecules of therapeutic use, such as an anti-tumour agent.

The present invention extends in various aspects not only to a substance identified as a modulator of ATM and p53 interaction and/or ATM or p53-mediated activity, property or pathway, in accordance with what is disclosed herein, but also a pharmaceutical composition, medicament, drug or other composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. for a purpose discussed elsewhere herein, which may include preventative treatment, use of such a substance in manufacture of a composition for administration, e.g. for a purpose discussed elsewhere herein, and a method of making a

pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.

A substance according to the present invention such as an inhibitor of ATM and p53 interaction may be provided for use in a method of treatment of the human or animal body by therapy which affects an ATM or p53-mediated activity in cells, e.g. tumour cells. Other purposes of a method of treatment employing a substance in accordance with the present invention are dicussed elsewhere herein.

Thus the invention further provides a method of modulating an ATM and/or p53-mediated activity, e.g. for a purpose discussed elsewhere herein, which includes administering an agent which modulates, inhibits or blocks the interaction of ATM with p53 protein, such a method being useful in treatment where such modulation, inhibition or blocking is desirable, or an agent which increase, potentiates or strengthens interaction of ATM with p53, useful in treatment where this is desirable.

The invention further provides a method of treatment which includes administering to a patient an agent which interferes with the interaction of ATM with p53. Exemplary purposes of such treatment are discussed elsewhere herein.

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule, mimetic or other pharmaceutically useful compound according to the present

invention that is to be given to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practioners and other medical doctors.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant.

Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Liposomes, particularly cationic liposomes, may be used in carrier formulations.

Examples of techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

The agent may be administered in a localised manner to a tumour site or other desired site or may be delivered in a manner in which it targets tumour or other cells.

Targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibody or cell specific

ligands. Targeting may be desirable for a variety of reasons, for example if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.

Instead of administering these agents directly, they may be produced in the target cells by expression from an encoding gene introduced into the cells, eg in a viral vector (a variant of the VDEPT technique - see below). The vector may targeted to the specific cells to be treated, or it may contain regulatory elements which are switched on more or less selectively by the target cells.

The agent (e.g. small molecule, mimetic) may be administered in a precursor form, for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. This type of approach is sometimes known as ADEPT or VDEPT, the former involving targeting the activator to the cells by conjugation to a cell-specific antibody, while the latter involves producing the activator, e.g. an enzyme, in a vector by expression from encoding DNA in a viral vector (see for example, EP-A-415731 and WO 90/07936).

An agent may be administered in a form which is inactive but which is converted to an active form in the body. For instance, the agent may be phosphorylated (e.g. to improve solubility) with the phosphate being cleaved to provide an active form of the agent in the body.

A composition may be administered alone or in

combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated, such as cancer, virus infection or any other condition in which a ATM or p53-mediated effect is desirable.

Nucleic acid according to the present invention, encoding a polypeptide or peptide able to modulate, e.g. interfere with, ATM and p53 interaction and/or induce or modulate activity or other ATM or p53-mediated cellular pathway or function, may be used in methods of gene therapy, for instance in treatment of individuals, e.g. with the aim of preventing or curing (wholly or partially) a disorder or for another purpose as discussed elsewhere herein.

Vectors such as viral vectors have been used in the prior art to introduce nucleic acid into a wide variety of different target cells. Typically the vectors are exposed to the target cells so that transfection can take place in a sufficient proportion of the cells to provide a useful therapeutic or prophylactic effect from the expression of the desired polypeptide. The transfected nucleic acid may be permanently incorporated into the genome of each of the targeted cells, providing long lasting effect, or alternatively the treatment may have to be repeated periodically.

A variety of vectors, both viral vectors and plasmid vectors, are known in the art, see US Patent No. 5,252,479 and WO 93/07282. In particular, a number of viruses have been used as gene transfer vectors, including papovaviruses,

such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have used disabled murine retroviruses.

As an alternative to the use of viral vectors other known methods of introducing nucleic acid into cells includes electroporation, calcium phosphate co-precipitation, mechanical techniques such as microinjection, transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.

Receptor-mediated gene transfer, in which the nucleic acid is linked to a protein ligand via polylysine, with the ligand being specific for a receptor present on the surface of the target cells, is an example of a technique for specifically targeting nucleic acid to particular cells.

A polypeptide, peptide or other substance able to modlate or interfere with the interaction of the relevant polypeptide, peptide or other substance as disclosed herein, or a nucleic acid molecule encoding a peptidyl such molecule, may be provided in a kit, e.g. sealed in a suitable container which protects its contents from the external environment. Such a kit may include instructions for use.

In further aspects the present invention provides for the provision of purified ATM. Purified ATM, for instance about 10% pure, more preferably about 20% pure, more

preferably about 30% pure, more preferably about 40% pure, more preferably about 50% pure, more preferably about 60% pure, more preferably about 70% pure, more preferably about 80% pure, more preferably about 90% pure, more preferably about 95% pure, or substantially pure ATM is obtainable using DNA. Such DNA may be in any form which ATM binds, including single-stranded DNA, double-stranded DNA, nicked DNA, covalently closed DNA circles and so on. It is surprising that any and all of these are bound by ATM as shown experimentally below.

In one aspect the present invention provides the use of DNA for purifying ATM.

In another aspect the present invention provides a method of purifying ATM, the method including contacting ATM with DNA. A mixture of material including ATM may be contacted against immobilised DNA (e.g. on a bead or agarose, and either covalently or non-covalently such as via a specific binding molecule such as streptavidin or biotin) and molecules which do not bind washed off.

We have also established that ATM may be purified using NTA, preferably in the presence of Ni2+. The NTA may be on any suitable support such as agarose or sepharose.

Thus, a further aspect of the present invention provides the use of NTA, preferably with Ni2+, for purifying ATM.

Another aspect of the present invention provides a method of purifying ATM which includes, contacting ATM with

NTA, preferably with Ni2+ and washing off molecules which do not bind.

Purification using DNA may be combined with purification using NTA, preferably with Ni2+, sequentially or simultaneously.

Either technique may be used for identification of co-factors of ATM which modulate ATM activity, such as factors which affect the interaction between ATM and DNA.

The ATM contacted by DNA and/or NTA in a purification may be in a mixture of molecules, such as a cellular extract, such as from a cell of an A-T patient, a normal cell of an organism such as a human or a recombinant host cell expressing the protein from encoding DNA, such as a bacterial, eukaryotic (e.g. mammalian or yeast) or insect cell, such as in a baculovirus expression system. Purification may follow production of ATM recombinantly in a suitable expression system, such as a cell, by expression from encoding nucleic acid.

Following purification, ATM may be used as desired, e.g. in an assay for an agent which modulates its phosphorylation of p53 or other molecule, in raising or obtaining a specific antibody or other binding molecule, or in a therapeutic context such as to compensate in an individual for the absence of wild-type ATM (as in, for example, a patient with A-T).

Various further aspects and embodiments of the present

invention will be apparent to those skilled in the art in view of the present disclosure. Certain aspects and embodiments of the invention will now be illustrated by way of example and with reference to the figures discussed already above.

ATM binds to DNA

A biotinylated random ds 50-mer oligonucleotide was coupled to streptavidin iron-oxide particles and these were employed to recover DNA binding proteins from HeLa cell nuclear extracts. This approach revealed that ATM interacts with particles bearing this random piece of ds DNA (Figure 1A). This binding is due to the presence of DNA, since streptavidin iron-oxide particles alone are unable to bind ATM (Figure 1A). Importantly, the sequence specific DNA-binding protein Sp1 and the non-specific DNA interacting protein complex containing RNA polymerase II (Pol II) are both unable to interact stably with the random DNA fragment employed in these studies (Figure 1A). Furthermore, DNA-PK_{CS} present in the crude nuclear extract binds only very inefficiently to the immobilised DNA despite the fact that its DNA-targeting component Ku is present (data not shown). Notably, protein quantification reveals that, under conditions in which over 90% of ATM binds to the DNA-coupled particles, less than 2% of total nuclear protein is retained. Hence, the retention of ATM by DNA in these studies is highly specific.

The above assay revealed that ATM, or an ATM complex, is capable of binding to a random piece of duplex DNA. Additional studies revealed that ATM is also retained by particles containing another unrelated oligonucleotide, suggesting strongly that the interaction is not sequence-specific (data not shown). To investigate the DNA binding properties of ATM further, we tested a series of DNAs with a variety of sizes and architectures. In these studies, binding and initial washes were conducted in the presence of 50 mM KCl, then bound material was eluted by sequential washes at 100, 250 and 500 nM KCl. Figure 1B demonstrates that the interaction between DNA and ATM is dependent on the size of the DNA-duplex. Thus, with a ds 15-mer, some ATM is still present in the unbound fraction and most bound material elutes in the lower salt wash. However, as the duplex size is increased, it becomes progressively more effective at binding ATM, such that when ds oligonucleotides of 50 bp or larger are employed, binding of ATM is almost quantitative and all bound ATM elutes in the higher salt wash (Figure 1B).

Since a variety of DNA structures are known to be produced by IR and are present during DNA-repair processes, we assessed the ability of ATM to bind to various types of DNA structure. Thus, assays were conducted employing particles coupled to a ds 100-mer oligonucleotide bearing a nick, a single-strand to double-strand transition, a gap of 35 bp, or a 10 base insertion loop. Notably, under the

assay conditions employed, ATM binds to these DNA molecules with equal efficiency and apparent affinity as it does to the fully ds DNA oligonucleotide (Figure 1C). Additional studies show that ATM also binds effectively to ss DNA (Figure 1C) and that, as with ds-DNA, this binding is dependent on oligonucleotide length (data not shown). Furthermore, ATM binding in such experiments is competed effectively by linear and circular plasmid DNA, suggesting that DNA termini are not required for ATM binding (NDL, unpublished data). Taken together, these data show that ATM, or a complex containing this factor, is capable of interacting with DNA molecules containing a variety of different structures in an apparently non-sequence specific fashion.

Purification of ATM

To increase our understanding of ATM further, we decided to attempt to purify this protein to essential homogeneity and thus separate it from other DNA-binding proteins, DNA repair factors, and protein and lipid kinases. The purification strategy we developed is outlined in Figure 2A. Since ATM is expressed ubiquitously and is located primarily in the cell nucleus, HeLa cell nuclear extract was used as starting material. Because no biochemical assay was available for ATM protein function, we monitored its purification by Western blot analysis using antibodies raised against two different portions of the protein (Lakin

et al., 1996). This approach not only revealed the fractionation of ATM but also allowed us to pool fractions that were devoid of the abundant DNA-PK enzyme through simultaneously testing for the presence of DNA-PK_{CS} and Ku. In light of the DNA-binding properties of ATM, we employed a final DNA affinity step in the purification scheme (Figure 2B, lane 4). Silver staining demonstrates that this leads to an essentially homogenous preparation of a ~350 kDa polypeptide, and Western blotting studies reveal that this is recognised strongly by ATM antiserum ATM.B (Figure 2B). Since this protein is also recognised by two other antibodies raised to distinct regions of the ATM polypeptide (data not shown), we conclude that the purified protein is indeed ATM. As revealed in Figure 2B, whilst ATM is enriched throughout the purification procedure, Ku, DNA-PK_{CS}, and the abundant ss DNA binding protein Replication Protein A (RPA) are all efficiently removed. Quantitative Western blotting and silver-staining reveal that the final yield of ATM is approximately 25% and indicate that ATM is of relatively low abundance, comprising around 0.002% of total nuclear protein by weight.

Purified ATM possesses an associated p53 kinase activity

Notably, as for DNA-PK (Hartley *et al.*, 1995), purified ATM preparations were found to be devoid of detectable kinase activity towards PI and a variety of phosphorylated PI derivatives. Although we cannot exclude that ATM

phosphorylates these or related phospholipids under certain conditions or in the presence of additional components, we conclude that ATM is not a lipid kinase. To assay for possible ATM-associated protein kinase activity, we performed *in vitro* kinase assays using equivalent amounts of various recombinant or purified proteins that we speculated may be ATM substrates. Certain candidate substrates, such as DNA-PK_{CS}, Ku, proliferating cellular nuclear antigen (PCNA), and the 34 kDa subunit of RPA (RPA-p34), were chosen by virtue of their association with DNA damage detection and/or involvement in DNA repair. We also tested Sp1 and p53, since these are both good substrates for DNA-PK and because A-T cells display aberrant induction of p53 in response to IR. A final protein tested was $I_{\kappa}B$, since recent data have implicated this is an ATM target (Jung *et al.*, 1995; Jung *et al.*, 1997). Given that DNA-PK requires DNA ends for efficient protein kinase activity, we reasoned that this might be the case for ATM also, and therefore included a DNA oligonucleotide known to activate DNA-PK in all initial kinase reactions.

Notably, none of DNA-PK_{CS}, RPA-p45 and PCNA was phosphorylated efficiently by purified ATM (Figure 3A). However, longer exposures of autoradiograms reveals weak phosphorylation of both the 70 kDa subunit of Ku (Ku70) and Sp1 by ATM preparations (data not shown). Furthermore, prolonged exposures also reveal that ATM is capable of autophosphorylation (data not shown), consistent with

previous rough studies employing ATM that had been immunoprecipitated directly from crude cell extracts (Keegan *et al.*, 1996) (likely to contain all sorts of impurities). Most significantly, however, several independently purified ATM preparations were consistently found to phosphorylate p53 with high efficiency (Figure 3A) (contrary to the mentioned results of Keegan *et al.*). Taken together, these data reveal that, under our assay conditions, a protein kinase activity co-purifies with ATM that phosphorylates p53 efficiently, and Sp1 and Ku70 weakly. Importantly, DNA-PK efficiently phosphorylates p53, Sp1, Ku70 and RPA-p34 *in vitro*, revealing that the ATM-associated kinase activity exhibits a different substrate specificity from that of DNA-PK. This, together with the absence of detectable DNA-PK_{CS} or Ku in our ATM preparations argues strongly against the possibility that the ATM-associated protein kinase activity is imparted by DNA-PK contamination.

Although the above results reveal that a p53 kinase activity co-purifies with ATM, prolonged silver staining reveals additional polypeptides in our ATM preparations (data now shown). The possibility therefore existed that the p53 kinase activity that we had detected was not mediated by ATM but by a contaminating protein. To address this issue, we immunoprecipitated ATM from purified ATM preparations using polyclonal antibodies raised against either the N-terminal region (ATM.N) or an internal region (ATM.B) of the ATM polypeptide (Lakin *et al.*, 1996). After

washing the immunoprecipitated material extensively in the presence of 500 mM KCl and 0.1% Nonidet-P40, it was employed in kinase reactions using p53 as substrate. To establish the purity of the immunoprecipitated material, purified ATM was biotinylated and immunoprecipitated in parallel with ATM employed in the kinase reactions. The biotinylated precipitated proteins were then visualised by Western transfer and probing with streptavidin conjugated horseradish peroxidase.

As illustrated in Figure 3B, a biotinylated protein of approximately 350 kDa in size, the predicted molecular mass of ATM, is precipitated in these studies by anti-ATM antisera but not by pre-immune sera. Notably, no other proteins are consistently precipitated by both ATM antisera in these assays (a polypeptide of ~100 kDa is apparent in the ATM.N precipitation in Figure 3B but is not present in ATM.B immunoprecipitates and was not consistently observed in subsequent experiments using ATM.N).

Most importantly, these experiments revealed that p53 kinase activity is immunoprecipitated by the two ATM antisera. Greater ATM associated kinase activity is observed with ATM.N than with ATM.B, despite only slightly higher amounts of ATM being precipitated by ATM.N (Figure 3C). One possible explanation for this is that ATM.B, which recognises epitopes close to the ATM kinase domain, impairs ATM protein kinase activity. These studies show that the p53 kinase activity present in our ATM preparations follows

ATM through a further highly stringent immuno-affinity purification step, and suggest strongly that ATM directly mediates p53 phosphoylation. Although unlikely in our opinion, it remains a possibility that p53 is phosphorylated by a distinct polypeptide that has escaped our detection methods and which remains associated with ATM throughout the stringent purification and immunoprecipitation protocols employed.

ATM associated kinase activity is stimulated by DNA

Given that ATM can interact with DNA, we investigated whether ATM associated protein kinase activity is stimulated by a nucleic acid cofactor. To achieve this, we performed *in vitro* kinase assays using purified ATM either in the absence or presence of increasing amounts of DNA. Because previous studies have revealed that co-localisation of DNA-PK and Sp1 to the same DNA molecule increases phosphorylation efficiency (Lees-Miller *et al.*, 1992; Gottlieb and Jackson, 1993), we employed a linear plasmid molecule bearing multiple p53 binding sites.

These studies revealed that DNA addition leads to marked stimulation of p53 phosphorylation by DNA-PK (Figure 4A, middle). Strikingly DNA addition was also found to result in marked stimulation of p53 phosphorylation in reactions containing ATM (Figure 4A, top). Thus, purified ATM preparations contain a DNA-stimulatable p53 kinase activity. Longer exposures of autoradiograms reveal that

the ATM polypeptide is also subject to phosphorylation in such assays and that this phosphorylation is stimulated by DNA (data not shown). Experiments employing equimolar amounts of DNA-PK and ATM revealed that the stimulation of p53 kinase activity by DNA is similar for ATM and DNA-PK, and that the stoichiometry of p53 phosphorylation by ATM is at least as high as that catalysed by DNA-PK (data not shown). Although DNA-dependent kinase activity was consistently observed in ATM preparations, the degree of activation was variable. In this regard, additional polypeptides were apparent in several preparations that displayed high levels of DNA activatability. Thus, it is possible that co-purifying polypeptides may be involved in high level ATM DNA dependent kinase activity. Notably, DNA-PK and ATM preparations both displayed significant but low levels of p53 kinase activity in the absence of DNA. It is not currently known, however, whether this reflects bona fide DNA-independent phosphorylation or results from small amounts of DNA in the protein preparations. Parallel experiments using cyclin A/cdk2 demonstrate no increase of p53 phosphorylation upon DNA addition (Figure 4A), and a variety of other protein kinases that we have tested are not stimulated by DNA. These results therefore show that increased protein phosphorylation is not a general effect of adding DNA to p53 kinase assays and reveal that DNA-PK and ATM are highly unusual in their abilities to be stimulated by DNA.

We had established that ATM binds to various types of linear DNA molecule (see Figure 1). Our binding competition studies indicated that ATM also interacts with supercoiled and nicked DNA (data not shown). We tested whether ATM associated kinase activity is affected differentially by various DNA structures. p53 kinase assays were performed in the absence of DNA or in the presence of increasing amounts of either supercoiled or restriction enzyme-linearised plasmid DNA.

Notably, ATM is activated equally well by supercoiled and linear DNA (Figure 4B), and additional studies revealed that good activation also occurs with nicked plasmid DNA molecules (data not shown). By contrast, DNA-PK is stimulated strongly by linear but only weakly by supercoiled plasmid DNA (Figure 4B; based on previous studies, the weak activation by the latter probably reflects small amounts of nicked and/or linear DNA in the supercoiled plasmid preparation). These results are therefore consistent with data showing that ATM is able to interact with many different types of DNA structure. Furthermore, they show that, although ATM is analogous to DNA-PK in that its associated kinase activity is stimulated by DNA, the DNA cofactor requirements of the two enzymes are different.

ATM associated kinase activity is not inhibited by the PI 3-kinase inhibitors wortmannin and LY294002

Previous studies have shown that DNA-PK and mammalian

PI 3-kinase are inhibited efficiently by the sterol-like anti-fungal compound wortmannin, with IC50 values of ~250 nM and 5 nM, respectively (Okada *et al.*, 1994; Hartley *et al.*, 1995). We tested for the effect of this compound on ATM-mediated phosphorylation. As shown in Figure 5A, wortmannin addition has little or no effect on p53 phosphorylation mediated by purified ATM, even when high concentrations of wortmannin are employed that abolish DNA-PK activity completely in parallel assays (Figure 5A). To rule out the unlikely possibility that wortmannin inhibits ATM, but this inhibition is masked by a contaminating p53 kinase in our ATM preparations, wortmannin addition experiments were also conducted using ATM that had been immunoprecipitated from purified ATM preparations by antiserum ATM.B (Figure 5B). Again, no significant inhibition of p53 phosphorylation was observed.

Another compound that acts as a potent inhibitor of mammalian PI 3-kinase is the synthetic agent LY294002 (Vlahos *et al.*, 1994). Significantly, whereas LY294002 inhibits DNA-PK-mediated p53 phosphorylation strongly, with an estimated IC50 of 2.5 uM, this compound has no discernible effect on p53 phosphorylation by ATM (Figure 5C).

These findings further demonstrate that the DNA stimulated protein kinase activity of ATM is not mediated by contaminating DNA-PK, and show that, although the putative kinase catalytic domain of ATM is related to those of PI 3-

kinase and DNA-PK_{CS}, its response to the well-characterised PI 3-kinase inhibitors wortmannin and LY294002 are highly distinct.

ATM associated kinase activity phosphorylates p53 at three sites

In initial approaches to determine the site(s) of p53 that are phosphorylated by ATM, bacterially expressed p53 was radioactively phosphorylated by ATM in the absence of DNA. Under these conditions, ~0.2 moles of phosphate were incorporated per mole of p53. Labelled p53 was purified by electrophoresis, digested by trypsin, and the resulting products separated by reverse-phase HPLC. The eluted radioactive profile showed a major peak eluting at 11-12% acetonitrile, in addition to smaller slightly later eluting peak (Figure 6A; peak 1a and 1b). Phosphoamino acid analysis revealed that both peptides were labelled on Ser residues (data not shown). Sequence analysis of peak 1a revealed a single burst of ^{32}P radioactivity after the eighth Edman degradation cycle (Figure 6B). Notably, the elution conditions, peak profile and sequencing results of this peptide identify it as a 16 amino acid residue p53 trypsin fragment bearing phosphorylation at Ser-315. Consistent with this, phosphorylation by ATM and tryptic mapping of a p53 mutant in which Ser-315 is replaced by Ala revealed a complete loss of peaks 1a and 1b (data not shown). Furthermore, we have shown that synthetic peptides of the

p53 region containing Ser-315 are efficiently phosphorylated by ATM. We therefore conclude that, in the absence of DNA, our ATM preparation phosphorylates p53 on Ser-315.

Since Ser-315 is a known site for phosphorylation of p53 by cyclin dependant kinases (Bischoff *et al.*, 1990), we tested whether our ATM preparations contained contaminating cyclin dependant kinases. To do this, we phosphorylated p53 with ATM in the presence of [γ^{32}P]-ATP and increasing amounts of the cyclin dependent kynase inhibitors p21 and roscovitin (Meijer, 1996). Significantly, neither p21 nor roscovitin inhibited ATM associated kinase activity markedly, whereas these reagents inhibited control reactions containing cyclin A/cdk2 (Figure 7). Similar results were obtained with another cyclin dependent kinase inhibitor olomoucine (data not shown). These results therefore suggest strongly that the phosphorylation of the Ser-315 residue of p53 by ATM preparations is not mediated by contaminating CDKs.

Since DNA stimulates ATM associated kinase activity, we sought to determine whether this reflects increased phosphorylation of Ser-315 or is due to phosphorylation at other sites. Notably, addition of DNA to kinase reactions containing ATM did not significantly stimulate phosphorylation at Ser-315, but instead resulted in the production of a novel set of radioactive p53-derived HPLC polypeptide peaks, which elute at 28-29% acetonitrile (peaks 2a, b and c; Figure 6C). Phosphoamino acid analysis revealed that all three peaks contained peptides labelled at

both serine and threonine residues, suggesting either two distinctly labelled co-eluting peptides, or a single peptide containing both phosphoserine and phosphothreonine residues (data not shown). Radioactive peaks with similar elution properties were identified following phosphorylation of p53 by DNA-PK (Figure 6D) or casein kinase I (data not shown). Previous studies have revealed that both DNA-PK and casein kinase I phosphorylate the N-terminal region of p53 (Lees-Miller *et al.*, 1992; Milne *et al.*, 1992). Initial attempts to sequence p53-derived peaks 2a, 2b and 2c were unsuccessful, presumably because they possess blocked amino-termini. However, cleavage with endoproteinase Asp-N allowed sequencing of each. Notably, release of counts at cycles 9 and 12 of Edman degradation of peptide 2a reveals that the sites of phosphorylation correspond to p53 residues Ser-15 and Thr-18 (Figure 7E). Ser-15 has previously been demonstrated to be a phosphorylation site for DNA-PK (Lees-Miller *et al.*, 1992). However, no detectable DNA-PK exists in our ATM preparations (see above). Furthermore, wortmannin has no affect on levels of radiolabel incorporated into any of the p53-derived tryptic phosphopeptides by ATM (data not shown).

We therefore conclude that, in addition to constitutive phosporylation of Ser-315, a novel DNA dependent kinase activity is associated with ATM that targets Ser-15 and Thr-18 of p53.

Additional purification method for ATM

HeLa nuclear extract was applied to Ni^{2+} - NTA agarose (Qiagen). We found that ATM binds very tightly to this matrix, but not very well to Ni^{2+} - IDA matrices.

5 ml of nuclear extract was loaded onto a 1 x 2.5 cm column of Ni^{2+} - NTA agarose in the following buffer (Buffer D; 25 mM HEPES-KOH, pH 7.6, 100 mM KCl, 10% Glycerol, 1 mM $MgCl_2$, 20 mM imidazole). The column was washed extensively (10 column volumes) before applying a linear gradient of 20 mM - 500 mM imidazole in buffer D. Virtually pure ATM (as judged by silver stain analysis of 8% polyacrylamide gels) eluted near the end of the imidazole gradient. Less pure fractions of ATM eluted at the start of the gradient.

This provides a purification strategy for ATM that may be used alone, or in combination with various other chromatographic steps, e.g. DNA affinity chromatography as discussed already above.

Discussion

We have demonstrated that ATM is retained on immobilised particles bearing DNA molecules. Notably, ATM binds to both ds and ss DNA in vitro, and studies employing a variety of unrelated oligonucleotides provide indication that this interaction is not sequence dependent. By exploiting these and other biochemical properties of ATM, we have developed a strategy to purify this polypeptide from HeLa nuclear extracts to near homogeneity. The high purity

of our final ATM preparations and the fact that ATM in such preparations can re-bind to DNA provides indication that ATM interacts with DNA directly. Although this appears somewhat different from the situation with DNA-PKcs, which requires Ku to associate stably with DNA under our assay conditions, UV protein-DNA cross-linking has revealed that, in the context of the DNA-PKcs/Ku holoenzyme, DNA-PKcs does make close contacts with DNA (Gottlieb and Jackson, 1993). DNA-PKcs and ATM may interact with DNA through similar mechanisms.

Because the C-terminal region of ATM possesses homology to the catalytic domain of mammalian PI 3-kinase, it has been speculated that ATM may phosphorylate inositol phospholipids. However, despite conducting lipid phosphorylation assays under various conditions and with a variety of potential substrates, no ATM-associated lipid kinase activity was detected in our ATM preparations. These data are thus consistent with recent studies demonstrating that ATM-containing immunoprecipitates possess no detectable lipid kinase activity (Jung *et al.*, 1997). Although we cannot discount the possibility that ATM modifies particular PI derivatives under certain conditions or in association with additional cofactors, we tentatively conclude that, as has been proposed for DNA-PKcs (Hartley *et al.*, 1995) and FRAP (Brown *et al.*, 1995), ATM is not a lipid kinase.

In contrast, our purified ATM preparations consistently possess protein serine/threonine kinase activity.

Recently (Keegan *et al.*, 1996) have performed rough experiments which might suggest that ATM-containing immunoprecipitates phosphorylate an ~350 kDa polypeptide, suggesting that ATM can modify itself (though the preparations would have contained all sorts of impurities, including kinases). We observe that purified ATM preparations are capable of some degree of ATM auto-phosphorylation.

In addition, we have tested ATM for its ability to modify a variety of other polypeptides. Notably, despite the fact that IkB has been implicated as an ATM target by in vivo functional studies (Jung *et al.*, 1995) and has recently been reported to be phosphorylated by ATM-containing immunoprecipitates (Jung *et al.*, 1997), under our assay conditions we do not detect significant IkB phosphorylation by ATM. Although alternatives exist, one explanation for this discrepancy is that IkB phosphorylation detected in the studies of (Jung *et al.*, 1997) was mediated by a co-immunoprecipitating factor that is separated from ATM during our purification scheme.

Another protein that has been implicated as a possible ATM target by virtue of defective regulation in A-T cells is RPA (Liu and Weaver, 1993; Cheng *et al.*, 1996). However, we have been unable to detect significant phosphorylation of RPA by ATM, suggesting that ATM regulates RPA indirectly. In contrast to the above, we observe low but detectable phosphorylation of Sp1 and the 70 kDa subunit of Ku by ATM.

Although the significance of these phosphorylation events is uncertain, these findings raise the interesting possibilities that ATM plays a role in regulating Sp1-dependent transcription and controlling the activity of the Ku/DNA-PKcs holoenzyme.

By far the most efficient substrate for ATM that we have identified, however, is p53. Importantly, the p53 kinase activity we have detected consistently co-purifies with ATM, elutes from the final DNA affinity purification step with the same profile as the ATM polypeptide itself, and further co-purifies with ATM through an additional stringent immunoprecipitation procedure. These data provide strong indication that p53 kinase activity is an inherent property of the ATM polypeptide.

In a manner strikingly reminiscent of the activation of DNA-PK by DNA strand breaks and ds to ss DNA transitions, we find that ATM associated p53 kinase activity is stimulated markedly by the addition of a DNA cofactor. There are several reasons why this DNA-stimulated protein kinase activity is unlikely to be mediated by contaminating DNA-PK. First, titration studies reveal that, to provide the observed level of p53 phosphorylation, the DNA-PKcs content of ATM preparations would have to be essentially as great as that of ATM itself. Clearly, this is not the case - silver staining and Western blotting reveal that, if any residual DNA-PK does exist in our most purified ATM preparations, it is present at levels undetectable by the methods employed in

this study. Second, the substrate specificity observed in ATM preparations is distinct from that of DNA-PK. Third, whereas ATM-associated kinase activity is stimulated equally by supercoiled and linear plasmid molecules, DNA-PK is only activated strongly by the latter. Fourth, wortmannin and LY294002 inhibit DNA-PK but have little or no effect on ATM-associated kinase activity. In light of these points, we conclude that ATM is a novel DNA-stimulated protein kinase.

There are several possible ways in which ATM might be stimulated by DNA, and each of these may contribute to the effects that we observe. (The mechanism of action provides no limitation to the nature and scope of the present invention.)

One possibility is that DNA binding by ATM activates the catalytic potential of the protein directly. Another is that the co-localisation of ATM and its target DNA binding protein on the same DNA molecule serves to potentiate interactions between the kinase and its target. In line with one or both of the above models, we have observed that ATM auto-phosphorylation is also enhanced by DNA, albeit to a lesser degree than that observed with p53.

Alternatively, at least part of the dramatic stimulation of p53 phosphorylation upon DNA addition could be explained by the binding of p53 to DNA inducing a conformational change in p53 that makes it a more effective ATM substrate. One attraction of this model is that it would help explain why only two of the three ATM-mediated

p53 phosphorylation events are DNA dependent. Thus, whereas Ser-315 of p53 may be exposed constitutively for phosphorylation by ATM, Ser-15 and Thr-18 might only become accessible to ATM after p53 is bound to DNA. In accordance with such a model, it is known that the conformation of p53 does change upon binding to DNA (Halazonetis *et al.*, 1993), and it has been observed that several naturally occurring p53 mutants that are defective in sequence-specific DNA binding exhibit reduced phosphorylation at Ser-15 (Ullrich *et al.*, 1993).

Given the DNA-PK paradigm, and because of the previously described role of ATM in DNA damage signalling, it might be tempting to speculate that ATM protein kinase activity in vivo is triggered by specific types of DNA damage or stalled DNA replication forks that occur in response to IR. However, unlike DNA-PK, which is activated strongly in vitro only by DNA molecules bearing perturbations in the DNA double-helix, we find that ATM interacts equally well with all types of DNA structure that we have tested. It is, therefore, possible that ATM is active constitutively in mammalian cells. An alternative model, which we currently favour, is that ATM associates with other polypeptides rather like DNA-PKcs interacts with Ku, and it is the function of these additional components to restrict ATM activity under normal circumstances and only allow its activation after exposure to DNA damaging agents. In this regard, it is interesting to note that yeast genetic

data indicate the *S. cerevisiae* and *S. pombe* homologues of ATM function in conjunction with other polypeptides in DNA damage signalling (reviewed in Elledge, 1996; Carr, 1997), and that biochemical studies reveal that ATM exists as a large complex of ~2 MDa in crude cell extracts (GCMS, unpublished data).

Together with genetic data indicating that ATM functions upstream of p53 in a pathway for signalling IR-induced DNA damage, our findings provide indication that, following genomic insult, ATM phosphorylates p53 directly. Such a model would help to explain the deficient up-regulation of p53 in response to IR in A-T cells and this, in turn, would explain at least some of the cell cycle checkpoint control defects of A-T cells. Interestingly, recent studies indicate that ATM interacts with p53 directly (Watters *et al.*, 1997) providing a possible mechanism for optimising the efficiency of ATM-mediated p53 phosphorylation in the cellular context. Indeed, since p53 itself binds to DNA strand breaks and DNA insertion loops (Balkalkin *et al.*, 1994; Lee *et al.*, 1995; Reed *et al.*, 1995), p53 could actually play a role in targeting ATM to sites of DNA damage. A model in which ATM targets p53 directly is particularly attractive when one considers that the sites phosphorylated by ATM, Ser-15, Thr-18 and Ser-315, all reside in conserved and functionally important regions of the p53 polypeptide. Moreover, both Ser-15 and Ser-315 of p53 have been shown to be phosphorylated in vivo (reviewed

in Anderson and Lees-Miller, 1992; Steegenga *et al.*, 1996). In addition, although Thr-18 has not yet been identified as a physiological site for p53 modification, it is noteworthy that this residue is highly conserved in p53, and that around 8% of p53 phosphorylation in vivo occurs at Thr residues (Samad *et al.*, 1986). In light of these points, it will clearly be of great interest to analyse the phosphorylation status of p53 Ser-15, Thr-18 and Ser-315 in wild-type and A-T cells, and to determine their degree of phosphorylation in response to IR.

Previous studies have shown that phosphorylation of Ser-315 by cyclin dependent protein kinases increases p53 DNA binding activity (Wang and Prives, 1995), suggesting that the newly discovered ATM-mediated phosphorylation will have a similar effect. Interestingly, phosphorylation of the N-terminal region of p53 has been proposed to effect both the stability and the transcriptional activation potential of p53 (reviewed in Ko and Prives, 1996; Steegenga *et al.*, 1996). Indeed, mutation of Ser-15 impairs the capacity of p53 to prevent S-phase progression and affects p53 stability (Fiscella *et al.*, 1993). Furthermore, p53 mutants unable to activate transcription show reduced phosphorylation at this site (Ullrich *et al.*, 1993). Although no experiments have investigated the role of Thr-18 in p53 function directly, it is noteworthy that this residue forms part of the minimal p53 binding site for Mdm2, which functions as a negative regulator of p53 function (Oliner *et al.*, 1993).

Significantly, Mdm-2 binding has been linked both to repressing p53-dependent transcriptional activation and targeting p53 for degradation within the cell (Momand *et al.*, 1992; Oliner *et al.*, 1993; Kubbutat *et al.*, 1997). An attractive scenario, therefore, is that phosphorylation of p53 by ATM may inhibit Mdm2 interaction, thus both stabilising p53 and de-repressing its transcriptional activity. It is therefore possible that the targeting of three distinct residues of p53 by ATM serves to activate this factor by multiple pathways, leading to rapid and effective p53 induction in response to IR. Given the availability of ATM-deficient cells and the existence of biochemical and immunological assays for ATM, we can now make rapid progress towards addressing the models and towards establishing a detailed molecular understanding of the ATM-dependent DNA damage signalling system.

It is emphasized that suggested mechanisms of action and models for ATM and p53 function discussed above are presented without limitation to the nature and scope of the present invention.

EXPERIMENTAL PROCEDURES

DNA interaction studies

Oligonucleotides: one DNA strand containing a 5′ biotin group (indicated by a "B" below) was annealed with complementary oligonucleotide(s) and bound to streptavidin-

coated iron-oxide particles (Dynabeads; Dynal, Oslo, Norway). HeLa nuclear extract, or ATM enriched extract (Q-Sepharose pool; see below) was incubated on ice for 30 min. with the DNA-iron oxide particles. After washing with 5 x 0.5 ml of D* Buffer (25 mM HEPES-KOH, pH 7.6, 20% glycerol, 2 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 1mM Na Metabisulfite) containing 50 mM KCl, protein was eluted with 500 mM KCl D* buffer or in gradual stepwise manner with KCl concentrations of 100 mM, 250 mM and 500 mM in buffer D*. Fractions were analysed for ATM protein content by Western blotting using a previously described rabbit polyclonal antisera raised against amino acid residues 1980-2337 of ATM (Lakin *et al.*, 1996).

Oligonucleotides:

ds 15-mer: 5' B-CCTGCCCTTGCCTGA-3'

5' TCAGGCAAGGGCAGG-3'

ds 25-mer 5' B-CCTGCCCTTGCCTGACGCTATTAGT-3'

5' ACTAATAGCGTCAGGCAAGGGCAGG-3'

ds 50-mer

5' B-TTGTAAAACGACGGCCAGTGAATTCATCATCAATAATATACCTTATTTTG-3'

5' CAAAATAAGGTATATTATTGATGATGAATTCACTGGCCGTCGTTTTACAA-3'

ds 75-mer

5' BGATCGAATCCGATAGAGTATAGATAGAGTAAAGTTTAAATACTTATATAGATAG AGTATAGATAGAGGGTTCAAA-3'

5' TTTGAACCCTCTATCTATACTCTATCTATATAAGTATTTAAACTTTACTC TATCTATACTCTATCGGATTCGATC-3'

ss 50-mer

5′ B-TTGTAAAACGACGGCCAGTGAATTCATCATCAATAATATACCTTATTTTG-3′

For the following, a biotinylated 100-mer oligonucleotide (DYNO) was used as a "backbone" to which other oligonucleotides were annealed.

DYNO 5′ B-CCTGCCCTTGCCTGACGCTATTAGTTCATCTATTTGTTTTGCTAATTCGA TTGGAATCGAAACGGTCACATATTCTTTTTTGACTGATTTCCTCGGCATA-3′

nicked oligo, DYNO + DAM2 + DAM3: ds/ss transition, DYNO + DAM3; gapped ds oligo, DYNO + DAM3 + DAM5; 10 bp insertion, DYNO + DAM6.

DAM2:

5′ TATGCCGAGGAAATCAGTCAAAAAAGAATATGTGACCGTTTCGATTCCAA-3′

DAM3:

5′ TCGAATTAGCAAAACAAATAGATGAACTAATAGCGTCAGGCAAGGGCAGG-3′

DAM5: 5′ TATGCCGAGGAAATC-3′

DAM6:

5′ TATGCCGAGGAAATCAGTCAAAAAAGAATATGTGACCGTTTCGAATTAGCAAAAC AAATAGATGAACTAATAGCGTCAGGCAAGGGCAGG-3′

ATM purification

All steps were performed at 4°C. HeLa nuclear extract (20 ml) was applied to a Q-Sepharose column (35 ml, 1.5 x 20 cm) equilibrated in D* buffer (25 mM HEPES-KOH, pH 7.6, 20% glycerol, 2 mM $MgCl_2$, 0.2 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 1 mM Na Metabisulfite) containing 50 mM KCl. After washing with 2 column vol. of 50 mM KCl D*, protein was eluted with a continuous salt gradient of 50 mM - 500 mM KCl in D* buffer. ATM eluted between 160 and 200 mM KCl. Fractions containing ATM and devoid of DNA-PK (as judged by Western blot analysis) were pooled and, after diluting to 100 mM KCl in D* buffer, were loaded onto a heparin agarose column (1.5 x 6 cm) pre-equilibrated in 100 mM KCl D* buffer. The column was washed with 2 column vol. of 100 mM KCl D* buffer before eluting with a continuous gradient of 50 mM - 500 mM KCl in buffer D*. ATM was again followed by Western blot analysis and eluted between 200 and 220 mM KCl. Peak fractions were pooled and dialysed against 50 mM buffer D*. Peak ATM fractions were then incubated with gentle mixing for 1 h. with 200 μg biotinylated 50 bp ds DNA conjugated to streptavidin iron-oxide particles. Unbound protein was rebound to fresh DNA-iron oxide particles. Particles were collected via a magnet and were washed 5 x with 0.5 ml of 50 mM KCl D* buffer before eluting ATM with 2 x 75 μl 500 mM KCl buffer D*. Purified ATM was snap-frozen and stored at -70°C.

Immunological Methods

Western immunoblot analysis was performed as previously (Lakin *et al.*, 1996). Sp1 antisera were purchased from Serotec Ltd. (Oxford, UK). RPA-p70 and RNA polymerase II antisera were also utilised.

Immunoprecipitations were performed by incubating biotinylated or untreated purified ATM in parallel with serum for 1 h. on ice in D* buffer containing 50 mM KCl. Protein A Sepharose was added and the reaction incubated with slow rotation for a further h. at 4°C. Beads were washed at high stringency seven times in 500 µl of D* buffer containing 500 mM KCl and 0.1% NP-40. Biotinylated immunoprecipitated proteins were visualised by 7% SDS-PAGE followed by Western blotting and probing with streptavidin-conjugated horse-radish peroxidase. Un-biotinylated immunoprecipitated proteins were washed a further two times in 500 µl 1 x Z' buffer prior to addition to kinase reactions (see below).

Phosphorylation assays

Kinase reactions were performed in 20 µl containing: 10 µl Z' buffer (25 mM HEPES-KOH pH 7.9, 50 mM KCl, 10 mM $MgCl_2$, 20% glycerol, 0.1% NP-40, 1mM DTT); 11 fmol ATM, DNA-PK or cyclin A/cdk2; 50-100 ng substrate and 0-30 fmol of DNA. Reactions were assembled and incubated for 3 min. on ice prior to addition of 10 µCi [γ-^{32}P] ATP and incubation at 30°C for 15 min. Wortmannin (Sigma), LY294002, p21 or roscovitin were pre-incubated in kinase reactions for 3 min.

prior to the addition of [γ-^{32}P] ATP. Phosphorylated proteins were subjected to 7% SDS-PAGE and visualised by autoradiography.

Mapping of p53 phosphorylation sites

Recombinant p53 (10-20 pmol; purified as previously (Hupp *et al.*, 1992)) was incubated with 12-24 ng of purified ATM or DNA-PK in the presence of 100 μM ATP containing 10^6-10^7 cpm/nmol [^{32}P]-γATP under reaction conditions described above. Linearised (pG_{13}-CAT) or supercoiled (pBS-SK; Stratagene, USA) DNA were included in DNA-PK and ATM reactions, respectively, where indicated. After 30 min. at 30°C, reactions were terminated by transferring to an ice water bath. Following TCA precipitation, labelled p53 was resolved by 10% SDS-PAGE and visualised by autoradiography. The gel section containing labelled p53 was excised and the protein eluted and TCA precipitated as described (Alessi *et al.*, 1996). The washed TCA pellet was either digested directly with alkylated trypsin (Promega, Southampton, UK) or, for ASP-N digestion, solubilised first in 0.2% v/v Triton X-100 and digested overnight with 1:5 w:w Asp-N (Boehringer Mannheim) and, where indicated, followed by overnight digestion with trypsin. The supernatant containing digested protein was chromatographed on a Vydac 218TP54 C18 column (Separations Group, Hesperia, CA) equilibrated with 0.1% v/v triflouroacetic acid (TFA), and eluted with a linear acetronitrile gradient. The flow rate

was 0.8 ml/min. and 0.4 ml fractions were collected. Peak fractions were coupled covalently to a Sequelon acrylamide membrane and analysed on an Applied Biosystems 470A sequencer using the modified programme described by (Stokoe *et al.*, 1992) to determine Edman degradation cycle numbers corresponding to radioactivity release.

Additional Purification of ATM

Purification using NTA has been described already above.

REFERENCES

These references and all others mentioned herein are incorporated by reference.

Alessi *et al.*, (1996), *EMBO J.* **15**, 6541-6551.

Anderson *et al.*, (1992), *Gene Express*, 2, 283-314.

Artuso *et al.*, (1995), *Oncogene* **11**, 1427-1435.

Balkalkin *et al.*, (1994), *Proc. Natl. Acad. Sci. USA* **91**, 413-417.

Barlow *et al.*, (1996), *Cell* **86**, 159-171.

Beamish *et al.*, (1994), *Radiat. Res.* 138, S130-133.

Beamish, H. and Lavin, M.F. (1994), *Int. J. Radiat. Biol.* 65, 175-184.

Bischoff *et al.*, (1990), *Proc. Natl. Acad. Sci. USA* **87**, 4766-4770.

Brown *et al.*, (1995), *Nature* **377**, 441-446.

Brown, E.J. and Schreiber, S.L. (1996) *Cell* **86**, 517-520.

Brown *et al.*, (1997), *Proc. Natl. Acad. Sci. USA* **94**, 1840-1845.

Carr, A.M. (1997), *Current Opinion in Genetics & Development* **7**, 93-98.

Chen *et al.*, (1993) *Mol. and Cell Biol.* **13(7)** 4107-4114.

Chen, G and Lee, E.Y.-H P. (1996), *J. Biol. Chem.* **271**, 33693-33697.

Cheng *et al.*, (1996), *Radiother. Oncol.* **39**, 43-52.

Dutta *et al.*, (1993) *Nature* 79-82

Easton, D.F. (1994), *International Journal of Radiation Biology* **66**, S177-S182.

Elledge, S.J. (1996), *Science* **274**, 1664-1672.

Fiscella *et al.*, (1993), *Oncogene* **8**, 1519-1528.

Fitzgerald *et al.*, (1997), *Nature Genetics* **15**, 307-310.

Goffeau *et al.*, (1996) *Science* **274**, 546.

Gottlieb, T.M. and Jackson, S.P. (1993), *Cell* **72**, 131-142.

Gu *et al.* (1997) *Nature* **387** 819-822.

Hartley *et al.*, (1995), *Cell* **82**, 849-856.

Haupt *et al.*, (1997) *Nature* **387** 296-299.

Hunter, T. (1995), *Cell* **83**, 1-4.

Hupp *et al.*, (1992), *Cell* **71**, 875-886.

Jackson, S.P. (1995), *Current Biology* **5**, 1210-1212.

Jackson, S.P.. (1996), *Cancer Surveys* **28**; Genetic Instability in Cancer, 261-279.

Jackson, S.P. (1996), *Current Opinion in Genetics & Development* **6**, 19-25.

Jackson, S.P. and Jeggo, P.A. (1995), *Trends Biochem. Sci.*

20, 412-415.

Jung *et al.*, (1997), *Cancer Res.* 57, 24-27.

Jung *et al.*, (1995), *Science* 268, 1619-1621.

Kao *et al.*, (1990), *Virology* 179: 806-814.

Kapeller, R. and Cantley, L.C. (1994), *Bioessays* 16, 565-576.

Kastan *et al.*, (1992), *Cell* 71, 587-597.

Keegan *et al.*, (1996), *Genes & Dev.* 10, 2423-2437.

Keith, C.T. and Schreiber, S.L. (1995), *Science* 270, 50-51.

Khanna, K. and Lavin, M.F. (1993), *Oncogene* 8, 3307-3312.

Khanna *et al.*, (1995), *Oncogene* 11, 609-618.

Ko, L.J. and Prives, C. (1996), *Genes & Dev.* 10, 1054-1072.

Kubbutat *et al.*, (1997), *Nature* 387 299-303.

Kussi *et al*, (1996), *Science* 274 948-953.

Lakin *et al.*, (1996), *Oncogene* 13, 2707-2716.

Lee *et al.*, (1995), *Cell* 81, 1013-1020.

Lees-Miller *et al.*, (1992), *Mol. Cell. Biol.* 12, 5041-5049.

Li and Botchan, (1993) *Cell* 73 1207-1221.

Lieber *et al.*, (1997), *Current Opinion in Genetics & Development* 7, 99-104.

Lill *et al.* (1997) *Nature* 387, 823-827.

Lin *et al.*, (1994) *Genes & Development* 8: 1235-1246.

Liu, V.F. and Weaver, D.T. (1993), *Mol. Cell. Biol.* 13, 7222-7231.

Lu, X. and Lane, D.P. (1993), *Cell* 75, 765-778.

Maheswaran *et al.*, (1993) *PNAS USA* 90 5100-5104.

Martin *et al.*, (1992) *J. Biol. Chem.* 268(18) 13062-13067.

Meijer (1996), *Trends Cell Biol.* 6, 393-397.

Meyn, M.S. (1995), *Cancer Res.* 55, 5991-6001.

Milne *et al.*, (1992), *Oncogene* 7, 1361-1369.

Momand *et al.*, (1992), *Cell* 69, 1237-1245.

O'Connor *et al.*, (1995) *The EMBO J.* 14(24) 6184-6192.

Okada *et al.*, (1994), *J. Biol. Chem.* 269, 3563-3567.

Oliner *et al.*, (1993), *Nature* 362, 857-860.

Picksley *et al.*, (1994) *Oncogene* 9 2523-2529.

Poltoratsky *et al.*, (1995), *J. Immunol.* 155, 4529-4533.

Reed *et al.*, (1995), *Proc. Natl. Acad. Sci. USA* 92, 9455-9459.

Samad *et al.*, (1986), *Proc. Natl. Acad. Sci. USA* 83, 897-901.

Savitsky *et al.*, (1995a), *Science* 268, 1749-1753.

Savitsky *et al.*, (1995b), *Hum. Mol. Genet.* 4, 2025-2032.

Seto *et al.*, (1992) *PNAS USA* 89 12028-12032.

Shiloh, Y. (1995), *Eur. J. Hum. Genet.* 3, 116-138.

Soussi *et al* (1990) *Oncogene* 5 945-952.

Steegenga *et al.*, (1996), *J. Mol. Biol.* 263, 103-113.

Stokoe *et al.*, (1992), *EMBO J.* 11, 3985-3994.

Thut *et al.*, (1995) *Science* 267 (5194) 100-104.

Truant *et al.*, (1993) *J. Biol. Chem.* 268(4) 2284.

Ullrich *et al:*, (1993), *Proc. Natl. Acad. Sci. USA* 90, 5954-5958.

Vlahos *et al.*, (1994), *J. Biol. Chem.* 269, 5241-5248.

Wang *et al.*, (1995) *Nature Genetics* 10, 188-195.

Wang, Y. and Prives, C. (1995), *Nature* 376, 88-91.

Watters *et al.*, (1997), *Oncogene* **14**, 1911-1921.

Xiao *et al.*, (1994), *Mol. & Cell. Biol.* **14(10)** 7013-7024.

Xu, Y. and Baltimore, D. (1996), *Genes & Dev.* **10**, 2401-2410.

Zakian, V.A. (1995), *Cell* **82**, 685-687.


A.
-DNA
+DNA
Input
Flow through
Eluate
Flow through
Eluate
TM
ol II
Sp1


B.
[KCl]
ON
FT
ds 15mer
ds 25mer
ds 50mer
ds 75mer


C.
[KCl]
ON
FT
ss 50mer
Nick
ds/ss transition
Gap
10 bp insertion

Figure 1

A.


HeLa Nuclear Extract
Q-sepharose
160 -200 mM KCl
Heparin Agarose
200-220 mM KCl
DNA-affinity
500 mM KCl
~ Pure ATM

B.


Markers
Nuclear Extract
Q-sepharose
Hep-agarose
DNA-affinity
205 -
116 -
97 -
66 -
Silver staining
ATM
DNA-PKcs
Ku
RPA p70
Western blots

Figure 2


DNA-PKc
Ku
Sp1
p53
RPA
PCNA
IκB
ATM: + - + - + - + - +
200–
116–
66–
– 200
– 116
– 66
– 31

Figure 2W


B.
ATM.B
ATM.N
Pre-immune
α-ATM
Pre-immune
α-ATM
ATM
244–
139–
80–


C.
ATM.B
ATM.N
Pre-immune
α-ATM
Pre-immune
α-ATM
p53: + - + + - +
p53

Figure 4

A.


Linear DNA
ATM
p53
DNA-PK
p53
Cyclin A/CDK2
p53

B.


DNA
Linear
p53
Supercoiled
p53
ATM
Linear
p53
Supercoiled
p53
DNA-PK

Figure 5


A.
Wortmannin
–
ATM
DNA-PK


B.
Pre-immune
α-ATM
Wortmannin
–
–
–
p53


C.
LY294002
–
ATM
DNA-PK


a
ATM
1
^{32}P-radioactivity (10^{-1} x cpm)
% acetonitrile
fraction number
c
ATM + DNA
1
2
^{32}P-radioactivity (10^{-2} x cpm)
% acetonitrile
fraction number
d
DNA-PK
^{32}P-radioactivity (10^{-2} x cpm)
% acetonitrile
fraction number
b
Peptide 1a
Ser-315
^{32}P-radioactivity (cpm)
A L P N N T S S S P Q P K
amino acid sequence
e
Peptide 2a
S15
T18
^{32}P-radioactivity (cpm)
D P S V E P P L S Q E T F S
1 2 3 4 5 6 7 8 9 10 11 12 13 14
cycle of Edman degradation

6

Figure 6

7

Figure 7


A.
Cyclin A/CDK2
ATM
p21
p21
p53
B.
Roscovitin
p53
ATM
p53
Cyclin A/CDK2

ATM PROTEIN SEQUENCE

Figure 8

8


p53-H-1
p53-H-19
MetGluGluProGlnSerAspProSerValGluProProLeuSerGlnGluThrPheSerAspLeuTrpLysLeuLeuProGluAsnAsnValLeuSerProLeuProSerGlnAla
MetAspAspLeuMetLeuSerProAspAspIleGluGlnTrpPheThrGluAspProGlyProAspGluAlaProArgMetProGluAlaAlaProArgValAlaProAlaProAlaThr
Cys
Pro
ProThrProAlaAlaProAlaProAlaProSerTrpProLeuSerSerSerValProSerGlnLysThrTyrGlnGlySerTyrGlyPheArgLeuGlyPheLeuHisSerGlyThrAla
LysSerValThrCysThrTyrSerProAlaLeuAsnLysMetPheCysGlnLeuAlaLysThrCysProValGlnLeuTrpValAspSerThrProProProGlyThrArgValArgAla
MetAlaIleTyrLysGlnSerGlnHisMetThrGluValValArgArgCysProHisHisGluArgCysSerAspSerAspGlyLeuAlaProProGlnHisLeuIleArgValGluGly
AsnLeuArgValGluTyrLeuAspAspArgAsnThrPheArgHisSerValValValProTyrGluProProGluValGlySerAspCysThrThrIleHisTyrAsnTyrMetCysAsn
SerSerCysMetGlyGlyMetAsnArgArgProIleLeuThrIleIleThrLeuGluAspSerSerGlyAsnLeuLeuGlyArgAsnSerPheGluValArgValCysAlaCysProGly
ArgAspArgArgThrGluGluGluAsnLeuArgLysLysGlyGluProHisHisGluLeuProProGlySerThrLysArgAlaLeuProAsnAsnThrSerSerSerProGlnProLys
LysLysProLeuAspGlyGluTyrPheThrLeuGlnIleArgGlyArgGluArgPheGluMetPheArgGluLeuAsnGluAlaLeuGluLeuLysAspAlaGlnAlaGlyLysGluPro
GlyGlySerArgAlaHisSerSerHisLeuLysSerLysLysGlyGlnSerThrSerArgHisLysLysLeuMetPheLysThrGluGlyProAspSerAspEND

Figure 9

PCT application number = PCT/GB 98/02115

Filing date of 23/47 - 16-7-98

Agent - Mewburn Ellis